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Abstract 
 
The complete blood count (CBC) is one of the most commonly performed tests in hematology 
laboratories. It’s useful in the diagnosis of many diseases such as anemia, infections and 
certain cancers. The accuracy and precision of the CBC require the implementation of a 
quality assessment program which should include two parts, the internal quality control (IQC) 
and the external quality assessment scheme (EQAS). The IQC program ensures that the 
laboratory delivers a reproducible results, while the EQAS controls the interlaboratory 
harmony.   
 
In the West Bank - Palestine, the accuracy and harmony of laboratory tests’ results including 
the CBC results has not been evaluated. Therefore this study aimed to evaluate and reflect the 
status of accuracy and harmony of CBC results using fresh whole blood samples. Sixty 
medical laboratories participated in this study. Three blood samples were distributed to the 
participant laboratories at three rounds with an interval of 22 days in-between. The CBC 
results were interpreted using the Deviation index (DI) method. The DI score for any test has 
been interpreted depending on the UK-NEQAS classification.  
 
The CBC results showed large variations among participant laboratories and confirms the 
need for a national EQAS program. Statistical analysis of CBC results showed that the 
performance of participant laboratories is the same in the three rounds and there is no 
improvement in all rounds.  
 
Among the participants, only 18.3% of laboratories have participated in an EQAS program 
because participation in an EQAS is not enforced by the local health regulations. Concerning 
the use of blood calibrators, 26.6% of participants use three calibrators while 66.7% of 
laboratories use only normal calibrator. Laboratories that use three calibrators have on average 
achieved better performance (based on DI scores) compared to those who use only one 
calibrator.  
v 
 
Also, 6.7% of the participant laboratories do not run any type of calibrators. Analysis of the 
frequency of calibrator use showed that 64.0% of laboratories use their calibrators on daily 
basis and 36.0% of laboratories use it at a lesser frequency.  
 
The inconsistency in the type or frequency of blood calibrator use among participant 
laboratories indicates a poor understanding of the principles of the work and calibration of cell 
counter. The study showed a poor harmony of CBC results in the hematology laboratories in 
Wes Bank and revealed the need for a national EQAS in the hematology laboratories in 
Palestine to reach a common level of standardization.  
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Definitions 
 
Accuracy: is defined as the best estimate of the result to the true value (Ciesla, 2007). 
 
External quality assessment scheme: the assessment of results from measurements produced at 
a certain site by comparing the results obtained by other sites or from the same material 
distributed by an external agency which analyses the data statistically (Lewis, 1998).  
 
Internal quality control: internal quality control comprises all steps of activity from assessing 
clinical needs, via collection of sample and measurement of a measurable quantity to 
reporting of results of measurement (Lewis, 1998).  
 
Precision: the reproducibility and repeatability of test samples using the same methodology on 
two or more occasions (Ciesla, 2007; Shinton et al., 1982).   
 
Quality assessment program: the sum total of a laboratory's activities aimed at achieving the 
required standard of analysis (Lewis, 1998). 
 
Range: is the difference between the largest and the smallest values in a data group (Stiene-
Martin, 1998)  
 
Sample: is a material available for analysis (Lewis, 1998). 
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Chapter One: Introduction 
 
 
1.1. Introduction. 
 
Medical laboratory is the first front line in the diagnosis of diseases in the diagnostic 
medicine. All kinds of laboratory tests need a Quality Control (QC) program which is 
considered as the foundation stone for the medical laboratory to achieve precise and accurate 
results. QC is a systematic method that ensures a laboratory maintains standards and 
reliability in reporting a test result (Saxena et al., 2007). For a medical laboratory that serves a 
real purpose, the results of the tests must be correct and reliable. The tests themselves must be 
relevant for the diagnosis and clinical care of patients, and for health screening and 
epidemiological studies as well (Lewis, 1998). 
 
Clinicians rightly expect that medical laboratories should provide reliable reports of the 
results of tests which would help them in the diagnosis, monitoring and in the management of 
their patients (Lewis, 1988). The main task of the medical laboratory is to provide an effective 
answer to clinical requests and to help clinicians in making decisions for their patients 
(Sciacovelli et al., 2006).The medical laboratory must be efficient, effective and as 
economical as possible without sacrificing its standards (Lewis, 1998). To achieve these 
objectives of good laboratory practice that requires skilled management with critical 
supervision of the work, the laboratory must include a Quality Assessment Scheme (QAS) 
(Lewis, 1998). QAS is concerned with all aspects of a laboratory practice. The QAS includes 
two program components namely Internal Quality Control (IQC) and External Quality 
Assessment Scheme (EQAS), in addition to the Proficiency Surveillance (PS) and 
standardization (Lewis, 1998).   
 
The hematology laboratory performs many medical laboratory tests including the Complete 
Blood Count (CBC), Blood Film (BF), Erythrocyte Sedimentation Rate (ESR) and molecular 
hematological tests for certain diseases. But the major test in the hematology laboratory is the 
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CBC which consists of many important hematological parameters depending on how much 
advanced the cell counter is. CBC with WBCs differential counts is a powerful tool that helps 
identify specifically which WBC line is affected in a certain disease. CBC is considered one 
of the most frequently ordered laboratory tests in medicine (George-Gay and Parker, 2003). It 
helps diagnose the causes of a lot of diseases as a screening test, but also may help to confirm 
that cause like an infection if present, and suggests a potential need for further testing 
(http://www.labtestsonline.com). The main nine components of CBC are the Red Blood Cells 
(RBCs), Hemoglobin (Hgb) , Hematocrit (Hct), Red Blood Cell Indices which include Mean 
Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular 
Hemoglobin Concentration (MCHC), Red Blood Cell Distribution Width (RDW), White 
Blood Cells (WBCs), and Platelets (Plts) counts (Dixon, 1997). Mean Platelet Volume (MPV) 
is another useful hematological parameter used in monitoring recovery in thrombocytopenia, 
but it is less commonly used by clinicians for treatment of other diseases (Buttarello and 
Plebani, 2008).  
  
CBC needs a blood sample drawn from a vein in the arm of an adult or sometimes from a 
finger or a heel in babies, and it is used to determine the general health status and to screen for 
and monitor a lot of diseases as part of a routine medical examination. A major cause of error 
is the fact that in a busy medical laboratory, where many samples are handled in a day, it may 
not be possible to give sufficient attention to every sample (Lewis, 1988). Still the results 
must be presented, without undue delay, to the clinician or public health worker who has 
requested the tests. The report should be legible and readily understood to provide help for a 
clinical diagnosis and for management of a patient or for health care of a population at large 
(Lewis, 1998). Many diseases or disorders result in increase or decrease of the different parts 
of the blood that can be detected by the CBC test which is used as a broad screening test. In 
hematology, the target value is the consensus median value of the participant medical 
laboratories using the same kind of cell counter, (Martins et al., 1995). In the West Bank, 
there are many types of cell counters which are used and thus need another formula to work 
out its performance. There are two methods used in EQAS. These are the consensus method 
and the assigned value method (Lewis, 1998). This study adopts the consensus method.  
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1.2. Problem statement. 
 
As a primary test, CBC is used for evaluating hematologic disorders, diagnosing infections, 
monitoring chemotherapy and radiation, and for the treatment of infection. However, it can be 
a powerful tool in the hands of the informed clinician (George-Gay and Parker, 2003). So the 
evaluation of the QC for the CBC test is essential. Nowadays, only the nine basic 
hematological parameters are involved in the international EQAS programs, like United 
Kingdom National External Quality Assessment Scheme (UK-NEQAS) 
(http://www.ukneqas.org.uk), Randox International Quality Assessment Scheme (RIQAS) 
(http://www.riqas.com/) and the College of American Pathologists (CAP) 
(http://www.cap.org/apps/cap.portal).  
 
In the West Bank, it seems that the variation in the hemogram results among the medical 
laboratories is large enough, and the harmony of the results is poor which unveils a need for 
implementing a national quality control program. Therefore, there is a strong demand for 
implementing EQAS in the West Bank in order to ensure harmonization of results among 
medical laboratories. This harmonization would enable all medical laboratories to achieve 
results which are in agreement with each other and then identify the outlier laboratories. The 
success of the scheme implementation will provide an opportunity to widen the scope of the 
participant medical laboratories.  
  
1.3. Justifications. 
 
This study is expected to show the need for a national EQAS in the hematology laboratories 
and to reach a common level of standardization. It will also help in the development of a plan 
for harmonizing CBC test results in the West Bank. In addition, it will contribute to the 
implementation of an EQAS in the West Bank by establishing a basic scientific background 
for a QC plan. This would suggest that only medical laboratories involved in quality 
assessment programs should be licensed to perform laboratory tests, which would guarantee 
better patient care and management, and enhance the reliability of the medical laboratory tests 
(Sah et al., 1999).  
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Local EQAS programs run by the department of Medical Laboratory Sciences at AL –Quds 
University has evaluated a few hematological parameters in the CBC, but this study is the first 
that covered the nine hematologic parameters. Another contribution that this study offers is 
providing the participating medical laboratories with a free access to an EQAS. Since the 
application of this consensus study provides the participating laboratories with feedback on 
the consistency and precision of their performance. These medical laboratories are commonly 
unable to afford the international EQAS programs.    
 
1.4. Goals. 
 
CBC is a one simple automated test and each hematological parameter in the CBC test is a 
specific test and has its medical value in the diagnostic medicine. A routine hemogram is the 
most frequent test done for any person seeking medical help and most other (specialized and 
not-so-specialized) hematology tests are planned based upon the information obtained from 
the hemogram (Varma, 2007) .  
 
This study will reflect the status of harmony of the results, consensus and accuracy in 
hematology laboratories in the West-Bank. It will also evaluate the performance of Palestinian 
medical laboratories in the routine hematological parameters of WBCs, RBCs and Plts counts 
and the red cell indices which include the MCV, MCH and MCHC. Also, the Hgb, Hct and 
RDW will be assessed to see if the consensus, accuracy and precision of the results currently 
achieved in the Palestinian medical laboratories meet the medically useful criteria for 
analytical performance in hematology laboratories. The evaluation of the quality control in the 
hematology laboratory in West Bank is essential since there is no national EQAS running in 
the medical laboratories at present.  
 
The outcome of the study will provide new updates in the field of QC, since no sufficient 
local studies are done recently in this filed. This study aims to provide a profound 
understanding of the medical diagnostic value of the CBC for medical laboratory scientists 
and clinicians as there has been a great acceleration in the medical information during the last 
two decades. 
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1.5. Automated hematology: where do we stand? 
 
The hematology laboratory is an essential component of the hospitals - based medical 
laboratories as well as private laboratories in West Bank, as in many other hospitals and 
laboratories around the world (Bunyaratvej et al., 1999). At macro scale, hematology 
laboratories particularly the CBC test have served a large number of populations in West 
Bank. It is the responsibility of the technician or the technologist in charge in the hematology 
laboratory to ensure that the tests which are performed are relevant, and that the results are 
reliable, reproducible and as accurate as possible (Lewis, 1998).  
 
Numerous studies have established that CBC is a key test for identifying many diseases of 
hematological and non- hematological origins, and clinicians rightly expect that the medical 
laboratories should provide reliable reports of the results, which would be very helpful in the 
diagnosis and in the management of their patients (Lewis, 1988). EQAS can be used to obtain 
a correct value for an analyte or a biochemical material. But the QA is concerned with all 
steps from specimen collection to transmission of the report to the clinician, and the 
participation in an EQAS will help produce reliable and accurate reporting of patient results.  
 
In 1932, Wintrobe developed a set of calculated indices that estimated the erythrocytes size 
and hemoglobin content based on RBCs, Hgb and Hct which are MCV, MCH and MCHC 
(George, 2005). Automation leads to many new advances in the hematological concepts and 
provide rapid and accurate RBCs, WBCs and Plts counts that establish new hematologic 
parameters, which are hoped to yield information that help in the diagnosis and treatment of 
some certain hematologic and non-hematologic disorders (Ward, 2000). During the first 
decade of the twenty one century, the advances in biochemistry, molecular biology and 
immunology led to introducing many new parameters that are found in the advanced cell 
counters, new instruments were made and new technologies were introduced like the flow 
cytometry technology. With the explosion of new instruments appearing in the market, and 
since there are many cell counters producing companies in the world that produce many kinds 
of cell counters, medical laboratories in the West Bank like, all laboratories around the world, 
use these cell counters and it is impossible to prefer any cell counter over another. 
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1.6. Understanding the complete blood count. 
 
CBC has multiple clinical applications and the test is usually done to investigate diseases like 
anemia which is the most frequent hematological disorder in childhood (Saxena et al., 2007). 
CBC evaluates medical conditions that secondarily affect the blood and bone marrow 
resulting in hematologic manifestations such as infection, inflammation, coagulopathies, 
neoplasms, and toxic substance exposure (George-Gay and Parker, 2003). The understanding 
of this test will help both the clinician and medical laboratory scientist identify a disease. For 
a full usefulness of the test, medical laboratory scientist, clinicians and hematologists must 
have a scientific background of the basic physiology and the life cycle of the blood cell types. 
CBC with differential WBCs count is one of the most common laboratory tests performed 
today and the value of each hematological parameter in the evaluation of a disease helps in 
diagnosing, treating and monitoring hematological disorders in addition to solving other 
medical problems (Tefferi et al., 2005).  
 
The clinicians who understand the CBC strength, limitations, and indications will find the test 
as an effective tool for avoiding more unnecessary tests and more costly tests for their 
patients. The benefits of the CBC for clinicians are varied. Sandhaus and Meyer (2002) 
reported that most CBC parameters are usually reported as percentages rather than absolute 
counts, and many clinicians do not use much of the data provided in the routine CBC. As a 
consequence of the dynamic changes in hematology laboratory, CBC, differential WBCs 
count, and reticulocyte count reports have tended to become longer and more complicated, 
and because of that clinicians might be receiving more data than they want. These excess data 
are not useful to clinicians and might affect their perception and comprehension of data and 
contribute to error in medical judgment (Sandhaus and Meyer, 2002).  
 
Still, CBC is an effective and efficient tool to obtain medical information on what is going on 
in the human body as hematology is a part of the laboratory medicine which is an Evidence 
Based Medicine (EBM). It is in every clinician’s interest to have some understanding of the 
specific test basics as well as a structured action plan when confronted with abnormal CBC 
results (Tefferi et al., 2005). 
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1.7. The physiological basis of the complete blood count: a scientific background. 
 
The CBC is a medical laboratory test that measures the circulating blood cells which are 
RBCs, Plts and total WBCs with its subtypes (Tefferi et al., 2005). Under the normal 
conditions, only mature blood cells should be found circulating in the peripheral blood. These 
mature blood cells are used to give information about the production of all blood cell lines by 
evaluating the immune system through the measurement of WBCs, and its subtypes the 
myeloid and lymphoid cells, and the oxygen – carrying capacity , through the measurement of 
Hgb, Hct and the RBCs indices and the PLTs counts (George-Gay and Parker, 2003). 
 
CBC is the test that measures all blood cell lines. These cell lines are originated from a mother 
cell which is the Pluripotential Stem Cell (PSC) in a process called hematopoiesis (George-
Gay and Parker, 2003). Hematopoiesis or hemopoiesis is the process in which the 
hematopoietic stem cells that have the ability both for self-renewal and to transform into all 
other cellular components of the blood, proliferate and differentiate giving rise to all blood 
cell lines (Dixon, 1997; Proytcheva, 2009).  
 
All blood cells are produced in the bone marrow from the PSC. This PSC undergoes 
successive stages of differentiation until it becomes committed cells (Dixon, 1997). The 
formation of blood cells in human is a complex process, and it depends on the human 
development. In an embryo, the process is divided into three periods which are named 
depending on the main sites of production. The first period is the mesoblastic period, and it 
continues for eight weeks from gestation. The first stem cell is derived from the mesoderm of 
the embryo; then tiny blood islands appear in the yolk sac and their outer cell form the blood 
vessels and the inner cells forms the hemoblast, the first primitive RBCs (Dixon, 1997; 
Proytcheva, 2009).  
 
The second period is the hepatic period which takes place in the liver, the main site of the 
blood formation in this period. This period starts from the second month and continues into 
the seventh month. Also the spleen begins to produce and contribute in formation of the blood 
cells (Dixon, 1997; Proytcheva, 2009).  
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In the third period which begins in the fourth month in the thymus, lymph nodes and the bone 
marrow are the main sites of blood production. The role of the bone marrow is the formation 
of all blood cell lines while the role of the thymus and lymph nodes is to complete the final 
development and activation of the immature WBCs (Dixon, 1997).  
 
The WBCs are derived from both myeloid and lymphoid stem cells. The mature myeloid cells 
have four forms the basophiles, eosinophils, neutrophils and monocytes. The first three cells 
are called granulocytes (Dixon, 1997). Granulocytes get their name from the granules present 
in their cytoplasm and these granules contain biochemical mediators as histamine, serotonin 
and heparin in basophiles. Additionally, granulocytes contain enzymes capable of destroying 
microorganisms or down regulating the hypersensitivity reactions by neutralizing the 
histamine as in eosinophils  (George-Gay and Parker, 2003).  
 
Non - granulocytes are another cell type which lack granules in their cytoplasm like the 
monocytes, the largest of the WBCs, which are considered as the cleanup crew of the human 
body with the macrophages  (George-Gay and Parker, 2003). A granulocytes include the other 
mature lymphoid cell types or they are called the lymphocytes that include the T cells, B cells 
and Natural Killer Cells (NK) (Dixon, 1997).  
 
Neutrophils or Poly Morphonuclear Neutrophils (PMNs) constitute about 55 % to 75 % of the 
leukocytes, whose main role is defending the human body against bacteria. These are found in 
two pools; the circulating pool and the marginal pool (Dixon, 1997; George-Gay and Parker, 
2003). Neutrophils normally remain in circulation for 12 hours in the absence of infection or 
trauma (Dixon, 1997). The other granulocyte eosinophils make up about 1 % to 4 % of the 
WBCs and play the main role in killing the multi cellular parasites in addition to detoxifying 
the antigen antibody reactions, (Dixon, 1997; George-Gay and Parker, 2003). 
 
Basophiles found in circulation are the least granulocytes and they make up about 1 % and 
they play major role in hypersensitivity reactions; as the mast cells in tissues (Dixon, 1997). 
They are associated with systemic allergic reactions with unclear mechanism of action 
(George-Gay and Parker, 2003).  
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Monocytes are the largest cells of the WBCs (George-Gay and Parker, 2003). Monocytes 
constitute about 2 % to 8 % of the WBCs and they are considered the clean-up crew which 
clear the body's foreign microorganisms (Dixon, 1997).  Monocytes that enter the tissues are 
called the macrophages and they are named after the particular tissue that found in (George-
Gay and Parker, 2003). The macrophages can destroy the microorganism while keeping its 
cell surface markers and then pass the information to the lymphocytes ; lymphocytes with this 
surface molecule always find the microorganism and defend against it (George-Gay and 
Parker, 2003).  
 
Lymphocytes which are the second line of defense in the body make about one third of 
WBCs, i.e., 25 % to 45 % (Dixon, 1997). Their major two types are T cells and B cells. The T 
cells are responsible for the cell mediated immune process and constitute about 80 % of the 
circulating lymphocytes. The B cells represents 20 % of circulating lymphocytes and are 
responsible for the humoral immune response in the body and the production of antibodies 
(Dixon, 1997). The major function of WBCs or the leukocytes is to defend the human body 
against organisms and injury and are considered as the major players in the inflammatory / 
infection in the immune response (George-Gay and Parker, 2003). Each WBCs cell type has a 
unique defensive role and mechanism in defending the body from foreign substance and 
microorganisms (Dixon, 1997). T cells have several subtypes including, regulators and 
effectors  (George-Gay and Parker, 2003) .  
 
The regulator T cells, which  are so called due to their function in turning on or off the 
immune response, are also divided into subtypes; the helper T cell that is considered the 
master switch of the immune system and has the cluster of differentiation 4 (CD4) surface 
molecules, and the T suppressor cell that suppresses the immune response once the immune 
system controls the infection (George-Gay and Parker, 2003). The second subtype is the 
effector cells which also have two types; the T cytotoxic cell which has the cluster of 
differentiation 8 (CD8) that helps destroy cancer cells and virally infected cells. And the 
memory cells that provide long lasting immunity against particular microorganisms (George-
Gay and Parker, 2003). B cells constitute the body’s main humoral immunity team, when 
activated, it transforms into plasma cells which produce the antibodies (Dixon, 1997).  
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The last cells are the NK cells and they are so called because they do not have T or B markers. 
NK cells are non specific, but they are very effective against cancer cells and virally infected 
cells (George-Gay and Parker, 2003).  
 
Erythropoiesis is the production of RBCs from the bone marrow stimulated by low levels of 
oxygen via an oxygen-sensing system located in the kidney and also involves the 
erythropoietin hormone (George-Gay and Parker, 2003) .  
 
The single function for RBCs or the erythrocytes, which are small and flexible cells, is to 
supply the living tissues with oxygen when picked up in the lungs and remove the generated 
carbon dioxide waste from the cells to the lungs for excretion (Dixon, 1997; George-Gay and 
Parker, 2003). 
 
RBCs are produced from the RBC progenitors in the bone marrow. Those progenitors go 
through a chain of phases that lead to production of mature cells called RBCs or erythrocytes 
(Dixon, 1997). RBCs are considered as Hgb containers. They lack nuclei and thus cannot split 
and their lifespan is only 120 days in the peripheral blood (George-Gay and Parker, 2003).  
 
The process of metabolism in RBCs depends on many factors like amino acids, vitamin B12 
and folic acid which are needed for cell development and DNA synthesis. Iron is needed in 
Hgb synthesis; four atoms of iron are required for each complete Hgb molecule (Dixon, 1997; 
George-Gay and Parker, 2003). The RBCs production is a complex process that includes 
many biochemical and metabolic pathways like heme and Hgb synthesis, acquisition of iron, 
amino acids, vitamins and growth factors in the bone marrow and the formation of alpha and 
beta chains that forms Hgb (Dixon, 1997). In a CBC test, Hgb considered a general indicator 
of anemia or polycythemia (Tefferi et al., 2005). Hgb molecule is a heme-portion complex of 
two pairs of similar polypeptide chains. Hgb synthesis needs amino acids, vitamin B6 and iron 
(Dixon, 1997; Irwin and Kirchner, 2001). Each Hgb molecule has two alpha and two beta 
globin chains in human adults while iron and vitamin B6 are involved in the formation of 
heme, responsible for the color of the human blood (Dixon, 1997; George-Gay and Parker, 
2003).  
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Hct is a parameter that is calculated in most automated blood cell counters, and it represents 
the percentage of the total volume of RBCs relative to the total volume of whole blood in a 
blood sample (George-Gay and Parker, 2003). Hct is considered as an indirect measure of the 
oxygen carrying capacity in blood while Hgb provides a direct measure of oxygen carrying 
capacity of blood and seems to be more sensitive to determine anemia but still not a gold 
standard. Additionally Hct is considered one of the factors that play a vital role in blood 
viscosity (Quinto et al., 2006). The relationship between both Hgb and Hct is expressed by the 
hematologic parameter MCHC which is one of the red cell indices (Quinto et al., 2006).  
 
The smallest cells found in the blood are the platelets or thrombocytes and their lifespan is 
from nine to twelve days (George-Gay and Parker, 2003). They are derived from the myeloid 
stem cells and produced in the bone marrow through a series of stages, and like the RBCs, 
they lack nucleus (George-Gay and Parker, 2003). Seventy percent of the Plts are found in the 
circulation and the remaining part is in the spleen  (George-Gay and Parker, 2003). Plts play a 
vital role in the homeostasis since Plts have two main functions; the first is to help in closing 
the bleeding site by forming a plug along with the coagulation factors, and the second is the 
vascular repair (Dixon, 1997).  
 
1.8. The clinical usage of the complete blood count in diagnostic medicine. 
 
Automated WBCs and RBCs counts were used first in 1960s, and today a single instrument 
can perform the entire CBC with few sampling errors (Dixon, 1997). CBC has multiple 
clinical applications in medicine, and it is the key that clinicians use once they start to look for 
any abnormality or disease. CBC contains a lot of valuable medical information about the 
human body obtained from the hematological parameters of an instrument. The hematological 
parameters reach up to eighteen parameters in some instruments.  
 
The clinician should use the CBC to evaluate the human body since the CBC is a panel of 
tests that help in the diagnosis of any hematological disease or other non-hematological 
disorders. CBC is usually used as a screening test for patients who are asymptomatic and have 
no physical signs or have symptoms of a disease (George-Gay and Parker, 2003).  
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The evaluation of each hematological parameter of the CBC is essential. A non- hematologist 
should be able to address some, but not all CBC abnormalities (Tefferi et al., 2005). The basic 
nine components of a CBC that are tracked in this study are WBCs, RBCs, Plts, Hgb, Hct, 
RDW as well as the Red Cell indices, MCV, MCH and MCHC. In the evaluation of each 
hematological parameter it is very essential for the clinician and the medical laboratory 
scientist to figure out potential diseases as any abnormal increase or decrease in the value of a 
given parameter could indicate the presence of a specific disease. 
 
The  evaluation of the WBCs or the leukocytes begin with examining of the total WBCs count 
and then examining the differential WBCs counts (Tefferi et al., 2005). Leukocytosis is an 
increase in the WBCs count, and any count above 11,000 /µL is considered a Leukocytosis, 
which appear in infections, inflammations and in cancers or marrow disorders (George-Gay 
and Parker, 2003; Tefferi et al., 2005). The severe increase of the total WBCs above 100,000 
/µL as in Leukemia, will affect the circulation by increasing the blood viscosity and may lead 
to Venous Thromboembolism (VTE) (George-Gay and Parker, 2003). The decrease in the 
total WBCs below 4,500 /µL is called Leucopenia. Most commonly it is a manifested as 
neutropenia or lymphopenia, and it may indicate bone marrow failure or it could be due to the 
immunosuppressive therapy (George-Gay and Parker, 2003; Tefferi et al., 2005) . 
 
The evaluation of the WBCs subtypes includes granulocytes and agranulocytes. The increase 
in neutrophils count in blood is called Neutrophilia, and it indicates a bacterial infection, or in 
the case of severe elevation, it may relate to the Chronic Myelocytic Leukemia (CML). One of 
the principles in the differentiation of Neutrophilia is to distinguish between the type of 
elevation, a shift to the right will mean that there is an elevation in the segmented neutrophils 
which appears in cases such as burns, hemorrhage or injuries, but a shift to left means that 
there is an elevation in the band neutrophils, and there are immature cells released in the blood 
circulation as a result to acute bacterial infection or some cancer. The second type of 
granulocytes is eosinophils, and their increase or Eosinophilia is an indicator of multi cellular 
parasitic infection. The third type of granulocytes is basophiles and their increase or 
Basophilia is seen in allergy (George-Gay and Parker, 2003; Tefferi et al., 2005). 
Lymphocytes increase is called Lymphocytosis and it can be seen in viral infections such as 
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cytomegalovirus or mumps in addition to acute leukemia. While the increase in monocytes is 
called Monocytosis and appears in certain cancers and in the chronic infections (Tefferi et al., 
2005).  
 
The evaluation of the RBCs, Hgb, Hct and the red blood indices is also very important. RBCs 
count assesses the oxygen carrying capacity of blood, but it is also critical to evaluate the bone 
marrow function especially in marrow failure diseases. An increase in the levels of the RBCs 
is called Erythrocytosis and it results from many causes such as polycythemia vera, or 
dehydration while the increase in RBCs count is related to Hgb and Hct (George-Gay and 
Parker, 2003). The initial screening method for iron deficiency in clinical practice is the 
evaluation of Hgb or Hct, but additional laboratory tests are needed (Beutler et al., 2003). Hgb 
is a direct measure of anemia while Hct is an indirect parameter of measurement for anemia 
(Carneiro et al., 2007; George-Gay and Parker, 2003; Tefferi et al., 2005). The classification 
of many types of anemia depends on Red Cell Indices. Clinicians should first look at the 
MCV which allow placement of anemia into one of the standard classification of macrocytic, 
normocytic or microcytic anemia by narrowing down the diagnosis of the many types of 
anemia (Irwin and Kirchner, 2001). MCV describes the RBC by size or volume which is, the 
volume in femto-liters, of the average circulating RBCs (George, 2005).   
 
MCV less than 75 fl is usually correlated with thalassemia can help in the assessment of the 
diseases by differentiating the type of anemia from thalassemia (Muncie and Campbell, 2009). 
MCH which measures the average weight of Hgb in an RBC is correlated to MCV. They 
increase or decrease together, and this tells the medical technologist that the cell counter 
works correctly (George-Gay and Parker, 2003).While MCHC measures the average 
concentration of Hgb in an RBC per unit volume, and is considered a marker for some 
diseases like spherocytosis. 
  
Erythrocyte indices are helpful for monitoring iron status, and assessing the need for iron 
supplementation during erythropoietin therapy for anemia of renal failure (Goodnough et al., 
2000).  
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Plts count is a valuable parameter in evaluating the Plts status in the blood. In a patient with 
thrombocytopenia, or a decrease in the Plts, the CBC test may unveil a need for blood 
transfusion for a patient before some surgical procedures, or otherwise compel the clinicians 
to cancel a main or alternative surgery for that patient (George-Gay and Parker, 2003). Other 
types of thrombocytopenia include drug induced or spurious thrombocytopenia which is 
caused by Ethylene-Diamine Tetra Acetic acid (EDTA) -induced platelet clumping (Tefferi et 
al., 2005). Thrombocytosis, which is the elevation of Plts greater than 1,000,000 /µL in the 
circulation, may be seen in a response to physical stress, infection or in myeloproliferative 
disorders (George-Gay and Parker, 2003).  
 
The last hematological parameter in this study is the RDW which is the coefficient of 
variation of MCV, and it represents the degree of size variation, or anisocytosis in the 
erythrocyte populations (Sandhaus and Meyer, 2002). The use of RDW in the diagnosis of 
Thalassemia is important as the molecular methods for the detection of the mutations are 
costly and not widely available. RDW may assist in differentiating iron deficiency anemia and 
sideroblastic anemia from Thalassemia, because RDW is elevated in these diseases more than 
in Thalassemia (Muncie and Campbell, 2009). 
 
Many new updates in hematology appear continuously. In Schizas study (2007), the 
researcher used the CBC hematological parameters to predict positive findings in anemic 
patients at endoscopy; the study found that in unexplained iron deficiency anemia, when the 
Hgb is less than 11 g/dl, the Hgb and Hct are useful hematologic parameters in endoscopy 
while MCV is not. Another relationship between disease and CBC was tackled in a recent 
study that observed that men with Hct and Hgb in the upper 20
th
 percentile are associated with 
increased risk for VTE compared to men in the lower 40
th
 percentile while MCV was not 
associated with VTE (Braekkan et al., 2009). The increase in Hct is associated with increased 
blood viscosity, reduced venous return and increased platelet adhesiveness (Braekkan et al., 
2009). The MCV and MCH at birth are quite reliable parameters for the prediction of alpha 
Thalassemia trait in neonates (Al-Hilali et al., 2009) which may provide a practical and cost-
effective test for screening for neonates' alpha-thalassemia. MCV less than 90 fl may predict 
the existence of alpha thalassemia.  
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1.9. Internal quality control and external quality assessment scheme in hematology.  
 
QC is a systematic method that ensures a laboratory maintains standards and reliability in 
reporting a test result (Saxena et al., 2007).The first national scheme was developed in the 
early 1960s in the USA by the College of American Pathologists (CAP), and many other 
national schemes were also established at about the same time in Canada, Australia, the 
United Kingdom and several European countries (Lewis, 1988).  
  
The two separate but complementary components in a laboratory Quality Assessment 
Program (QAP), the IQC and EQAS, play a role in achieving a reliable and reproducible 
report for the medical laboratories. IQC is comprises all steps of activity from assessing 
clinical needs, via collection of sample and measurement of a measurable quantity to the 
reporting of results of measurement. While EQAS is the assessment of results from 
measurements produced at a certain site by comparing the results obtained by other sites or 
the same material distributed by an external agency which analyses the data statistically 
(Lewis, 1998).  
 
Although EQAS is costly, it helps reduce health care costs. This statement wouldn’t sound 
paradoxical if we take into consideration the gross losses which poor QC entails. Needless to 
mention the value of clinician trust that QC guarantee. Quality control will result in reducing 
time and labour costs, and most importantly providing accurate patient diagnosis and 
treatment.  
 
IQC is concerned essentially with precision or reproducibility of results on a daily basis whilst 
EQAS is concerned with inter-laboratory and inter-method or inter-instrument 
harmony(Ciesla, 2007; Lewis, 1998). The main aim of the activities of an EQAS in laboratory 
medicine is to sustain improvements in the quality of services provided by participating 
laboratories for the benefit of patients (Sciacovelli et al., 2006). The understanding of the 
quality control of the CBC is very important; since CBC is one of the most common 
laboratory tests in medicine (George-Gay and Parker, 2003). Clinicians tend to accept the 
results of the electronic blood cell counters as accurate because of their high precision.  
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These counters simplify and speed the performance of blood counts and the calculations of 
red blood indices, but they are still imperfect and need IQC and EQAS (Herishanu and 
Berliner, 2002). In our modern era, IQC program for a routine hemogram should use 
commercial brand specific blood controls which are compatible with the cell counter brand 
since each blood control is designed for its machine. While what should be measured in the 
EQAS is the laboratory's accuracy using  blind samples that are analyzed as if they were 
patients samples (Lewis, 1998). 
 
With the explosion of new instruments appearing on the market, it is difficult if not 
impossible to favor a specific instrument over another at purchase time (Ward, 2000). In this 
context, EQAS play a primary role in the assessment and monitoring of all elements that 
contribute to the formulation of laboratory measurements (Buttarello and Plebani, 2008). The 
EQAS is an effective tool for clinical governance in laboratory medicine and now a wide 
range of instruments are available for blood counting (Sciacovelli et al., 2006).  
 
Initially the instruments were designed to analyze fresh blood and not stabilized cell 
suspensions which may not undergo the same shape change when diluted in the manufactures 
specific diluents (Lewis et al., 1991). This leads to the need of the EQAS with IQC that use 
commercial materials, since hematological test results are used for many clinical purposes 
including diagnosis, monitoring, screening, research and education (Fraser, 1990).QC has 
become mandatory in every field of medicine for measuring the quality of patient care  and 
the QAS  in hematology is intended to ensure the reliability of the tests done in the 
hematology laboratory (Sah et al., 1999). Three very important aspects of QC in hematology 
are calibration of the cell counter, monitoring accuracy and precision of the machine, and 
verifying the reliability of test results. A combination of commercial controls (three levels) 
and fresh blood is recommended (Gulati and Hyun, 1986). Nowadays, new parameters have 
been introduced to the CBC, and for a number of them there is no IQC or EQAS that raises 
the question whether these new parameters should be used for clinical decisions (Briggs, 
2009). In QC, EDTA is considered the anticoagulant of choice for automated cell counters. 
Blood samples should be analyzed as soon as possible. Storage at 4 degrees
 
Celsius may 
stabilize the samples for more than seventy two hours (Burgi, 1995; Buttarello, 2004). 
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1.10. Electronic blood cell counters and automation in hematology.  
 
In the 1960s, the first multichannel automated hematology instrument appeared based on the 
impedance technology designed by Walter and Joseph Coulter in 1956. Other technologies 
were developed later like the cell counting by light scattering that appeared in the 1970s 
(George, 2005). While the automation of the WBCs with differential for the three part 
differential began in the 1980s and the five part differential count was first introduced in the 
early 1990s (George, 2005). 
 
During the first half of the twentieth century, CBC was performed using exclusively manual 
techniques (George, 2005). The routine manual CBC is a labor-intensive test that lacks 
reproducibility. But rapid, accurate, and relevant laboratory testing is essential in an era of 
cost-effective medicine (Rappaport et al., 1988). In the past century until the early 1960s, 
hematologic evaluations were performed manually, and methods were labor-intensive and 
involved centrifuges, spectrophotometers, counting chambers with etched grids, and stained 
wedge smears of blood (Varma, 2007). 
 
In the last fifty years, physical sciences have undergone an evolution that led to many great 
achievements in the field of automated hematology, and CBC is worthy of special interest. 
Automated hematology 40 years later is still in its infancy, and in the first few decades of the 
new millennium advancing technology will routinely identify more white cell subtypes and 
even blast lineage while reducing the need for flags (Ward, 2000).  
 
Advances in technology over the next few decades will lead to sensitive and specific results of 
the CBC, but at the present time, the need for EQAS is important because automated 
hematology counters cannot provide these services. Advances in automated hematology 
instruments in the 1990s were made possible by new, improved, and cheaper computer 
processing technology and memory. Automated hematology counters have totally changed the 
landscape of the hematology laboratory since fewer manual techniques are required. The new 
automated blood cell counters offer accuracy and precision in counting process more than the 
old, manual methods did.  
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Nowadays instrument-driven hematology provides much accurate and precise data to 
clinicians (Ward, 2000). CBC gives information about the production of all blood cells lines 
and identifies the patient’s oxygen-carrying capacity through the evaluation of RBCs indices, 
Hgb, and Hct. It also provides information about the immune system through the evaluation of 
the WBCs count with differential in cases such as infection or inflammation (George-Gay and 
Parker, 2003). The new technology in the coming years will produce high clinical sensitivity 
which entails a better ability to distinguish between normal and pathologic samples in terms 
of quantitative anomalies and qualitative alterations like the presence of immature cells 
(Buttarello and Plebani, 2008).  
 
Instruments have to undergo evaluation at many levels using guidelines for evaluation in 
hematology laboratories (Shinton et al., 1982). Also the international consensus group for 
hematology was developed 83 rules. These rules hoped to be useful to a large number of 
hematology laboratories worldwide.   
 
Automated blood cell counters are becoming more and more sophisticated and the range of 
the reportable hematologic parameters available is increasing and giving more data about what 
is going on in the human body. So medical scientists and clinicians need to keep up to date 
with the new hematological parameters provided in the CBC (Briggs, 2009). 
 
The entire cell counters that were participated in this study used the coulter principle. The 
blood cells are sized and counted by detecting and measuring changes in electrical resistance 
when a particle passes through a small aperture. This principle is called the electrical 
impedance principle of counting cells (Figure 1). A blood sample is diluted in an isotonic 
solution, a good conductor of electrical current, and the cells are pulled through an aperture by 
creating a vacuum. And then two electrodes made an electrical current (Ciesla, 2007).  
 
The external electrode is located in the blood cell suspension. The second electrode is the 
internal electrode and is located in the glass hollow tube, which contains the aperture. Low-
frequency electrical current is applied to the external electrode and the internal electrode. DC 
current is applied between the two electrodes.  
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Electrical resistance or impedance occurs as the cells pass through the aperture causing a 
change in voltage. This change in voltage generates a pulse. The number of pulses is 
proportional to the number of cells counted. The size of the voltage pulse is also directly 
proportional to the volume or size of the cell (Ciesla, 2007).  
 
 
 
 
 
 
Figure (1.1) Coulter principle of electric impedance (adapted from, Ciesla, 2007) 
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1.11. Literature review. 
 
Many studies have been done since the first national scheme was developed in the early 1960s 
(Lewis, 1988). The WHO International External Quality Assessment Scheme (IEQAS) in 
hematology was started in January 1978 with 11 members, following a WHO interregional 
workshop on quality assurance and standardization in Thailand (Lewis, 1988). The 
organization of  IEQAS has been based on UK-NEQAS which has over 550 participants in the 
general hematology laboratory section, which was started in the 1968 
(http://www.ukneqas.org.uk; Lewis, 1998).  
 
UK-NEQAS has strongly participated in the progress and development of the EQAS 
programs around the world. In some IEQAS surveys the consensus obtained in the UK-
NEQAS is used when the same material is tested in both programs. When the material used 
for IEQAS differs from that used by the UK-NEQAS, the reference values of IEQAS 
materials are determined by the WHO Collaborating Centre at the Royal Postgraduate 
Medical School, London, using reference methods and reference standards in accordance with 
the protocols of the International Committee for Standardization in Hematology (Lewis, 
1988). 
 
For the qualitative procedures, correct results are similarly based on the UK-NEQAS peer 
consensus or the results from a group of references. In the beginning of EQAS for the basic 
laboratory tests in the developed countries, the participating laboratories cannot expect any 
financial support by any organization, nor public health, nor private assurance (Hu et al., 
2002). For example in Spain, the spanish hematology EQAS started in 1984 with fifty six 
medical laboratories, a number which rose to three hundred thirty two in 1989 (Vives-Corrons 
et al., 1991).  
 
For evaluation of results, laboratories are divided into four to eight groups depending on the 
methodologies used. Individual’s results are assessed against a consensus value (Mean), 
Deviation Index (DI) from the mean, Coefficient of Variation (CV %) and Youden diagram 
for all results and groups of each parameter. 
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In Germany, Quality control in hematology is performed in Germany for 20 years (Heller, 
1995). In France a national system for EQAS was stared in the 1970s, and about four 
thousand eight hundred laboratories are enrolled in the program, and all medical laboratories 
are financed by a fund that covers all their expenses (Sah et al., 1999). This national program 
has documented and improved the performance of those laboratories, and has helped the 
ministry of health to more efficiently manage the problems of laboratory medicine in France 
(LeBlanc and Goguel, 1990). Since 1970s, automated hematology has been introduced in Asia 
(Bunyaratvej et al., 1999). Local EQAS in shanghai has resulted in a reduction of the CV % 
values of CBC parameters (Xiaobo et al., 2003).  Thailand started an EQAS program in 1970s 
and about 800 out of 1300 laboratories are involved in this program (Opartkiattikul and 
Bejrachandra, 2002). The results of laboratory tests are evaluated by using participants' 
consensus values. In Jordan a study by Bilto, 1999, has shown that Jordanian laboratories 
were far from achieving the analytical goals. The latter study also stressed the need for a 
national EQAS in hematology, to reach a common level of standardization. 
 
In the West Bank - Palestine the department of Medical Laboratory Sciences at AL-Quds 
University started an EQAS program in the middle of 1995 with the corporation of the 
Medical Aid for Palestinian (MAP-UK) and the Higher Council of Health. They launched a 
limited EQAS that enrolled 72 medical laboratories belonging to governmental hospitals and 
other nongovernmental organizations (Shehadeh, 2000).. The scheme was suspended in 2001  
 
One of the limitations of this program is that the samples are preserved and not tested 
immediately; they stay in the medical laboratory for a long time before being tested 
(Shehadeh, 2000). This affected the blood sample properties in many ways physically, 
chemically and biologically. Another limited EQAS program was launched at the same time 
by Health Work Committees (HWCs) in West Bank. The HWCs scheme was similar to Al-
Quds University EQAS and has had the same limitations. Even though all possible 
precautions were taken to achieve reliable results by IQC, potential errors can arise. These are 
only detectable by EQAS. Since IQC achieves the precision which means the reproducibility 
but not necessarily the accuracy, it is obvious that both IQC and EQAS are essential tools for 
the medical laboratory. 
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Chapter Two: Materials and Methods  
 
 
2.1. Materials used in this study. 
 
The materials that have been used in the three rounds in this study were a phlebotomy tray and 
evacuated tube blood collection system as shown in Table 2.1:  
 
Table (2.1) Materials used in the study  
 
Number Item  Manufacture company 
1 Needles  ------------------ 
2 Tourniquet and holder ------------------ 
3 Evacuated tube blood collection system ------------------ 
4 1.3 ml plain tubes  ------------------ 
5 3.5 ml EDTA tubes ------------------ 
6 70 % isopropyl alcohol swabs ------------------ 
7 Sterile gauze swabs and Adhesive dressings ------------------ 
8 Rack and cork racks ------------------ 
9 Automatic pipette ------------------ 
10 Ice pieces ------------------ 
11 23 Liter refrigerators   Gaiter 
12 Thermometers ----------------- 
13 Anti - Human Immunodeficiency Virus (HIV) 1+2 strips Quick check 
14 Hepatitis B Surface Antigen (HBsAg) strips Quick check 
15 Anti - Hepatitis C Virus (HCV) strips Quick check 
16 Fresh venous human whole blood Three Volunteers  
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2.2. Preparation and distribution of the questionnaire. 
 
A two parts questionnaire has been prepared. Part one included basic information about the 
medical laboratory such as its name, laboratory director, address and telephones number, and 
the second part included eleven questions focusing on the QC components IQC and EQAS in 
each medical laboratory and the type and version of the cell counter used. The questionnaire 
was distributed to all medical laboratories.  
 
In Nablus which consists of thirty one medical laboratories, to survey about their acceptance 
to participate in this study. Twenty one medical laboratories agreed to participate in this study, 
while four medical laboratories rejected it. Four medical laboratories didn't have automated 
cell counters and two medical laboratories do not have automated cell counters and they rely 
on other neighboring laboratories to do CBC and one performs the CBC test manually. For 
Ramallah, the questionnaire was distributed to all medical laboratories in the city which has 
twenty six medical laboratories. Nineteen medical laboratories agreed to participate in this 
study, while six medical laboratories rejected it. One medical laboratory didn't have an 
automated cell counter. In Hebron, the questionnaire was distributed to all medical 
laboratories in the city which has twenty two medical laboratories. Twenty medical 
laboratories agreed to participate in this study, while two medical laboratories rejected it. All 
who volunteered to participate in this study have filled the study questionnaires.  
 
2.3. Preparation of the study samples.  
 
The main purpose of this study is to assess the performance of the Palestinian medical 
laboratories in West Bank on a routine CBC test. Sixty public and private medical laboratories 
participated in this study. These are distributed throughout the cities of Ramallah, Nablus, and 
Hebron.  
 
The cycle was repeated three times within the interval of twenty two days between successive 
cycles. Samples were tested between September and October 2010. The collection, 
preparation and the distribution of the samples were done in Ramallah city. 
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On the morning of the testing day, around 70 ml of venous blood was collected from a healthy 
adult male volunteer. The site of vein puncture was swabbed with Isoporpanol. The evacuated 
blood collection system was used with 3.5 ml tubes that contain EDTA as an anticoagulant. A 
rack was used to hold the blood samples upright during process of filling.  
 
Three healthy adult volunteers who donated the blood samples for this study was tested 
against Anti- HIV 1+2; HBsAg and Anti- HCV and the results were negative for all three viral 
markers. The blood in 3.5 ml tubes was pooled in a sterile box and mixed. The last step done 
at the end of the three rounds included testing tubes numbered 1, 20, 40, and 60 on a cell 
counter (CellDyn 1700) to test the consistency; The results are shown in appendix A. 
 
2.4. Distribution of the study samples.  
 
The pooled fresh blood was distributed into sixty polystyrene plain tubes of 1.3 ml volumes 
using an automatic pipette in which each tube contained 1 ml of homogeneous blood. The 
samples were given trial code numbers which were Quality Control Ramallah one, two and 
three (QCR1, 2 or 3), Quality Control Nablus (QCN1, 2 or 3), and Quality Control Hebron 
(QCH1, 2 or 3).  
 
Then the plain tubes containing EDTA blood were distributed into three refrigerators. Each 
refrigerator contained at least three ice pieces to provide a suitable environment for the blood 
samples and one thermometer that was graduated for both Celsius and Fahrenheit degrees to 
monitor the changes in the temperature during transportation of samples. Three volunteers 
took the charge of the transportation process in the three cities at the same time.  
 
Distribution was performed in such a way that within less than four and half hours after blood 
collection, each participating laboratory received one sample of 1.0 ml of EDTA whole fresh 
blood. Each medical laboratory was instructed to allow the sample to reach the room 
temperature before testing it on the laboratory’s cell counter and mix it for 10 times before 
testing it on the laboratory’s cell counter.  
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2.5. Temperature changes during blood samples distribution. 
 
Changes in the blood storage affect the blood samples in QC. The WBCs, RBCs and PLTs 
numbers are stable for more than 24 hours in the EDTA as an anticoagulant (Burgi, 1995; 
Buttarello, 2004; Hall, 1991). In this study blood samples were put in the refrigerator with ice 
pieces for less than four and half hours to ensure a suitable environment. Several variables 
may affect the blood samples such as the time, temperature and shaking. To provide the 
optimum environment for the blood samples and to stabilize these variables as much as 
possible, a cork was used in each refrigerator to prevent the shaking during the transportation 
of blood samples. For temperature, each refrigerator was provided with a thermometer to 
record the temperature of the box, while time was recorded by the distributers.  
 
In Ramallah, the temperature of the box in round one was 11
o
C
 
at the beginning of the 
distribution of the blood samples. Then the temperature decreased under the effect of the ice 
to 8
o
C
 
and it did not rise more than 10
o
C
 
when the last sample was distributed. The time from 
the beginning of distribution to the end was about four hours. In round two, the temperature 
was 4
o
C
 
then rose in the middle of the distribution to 5
o
C
 
and kept between 4 – 5oC to the last 
sample, while the time decreased to two hours since two volunteers participated this time in 
distribution. The temperature in round three started with 3
o
C
 
and increased with time to reach 
9
o
C
 
by the end of the distribution, while time was less than three hours.  
 
In Nablus, the temperature of the box in round one was 4
o
C
 
at the beginning of the distribution 
of the blood samples. Then the temperature increased in the last few samples to reach 5
o
C
 
and 
was kept at the same temperature to the end of sample distribution. The time from the 
beginning of the distribution to the end was about four hours. In round two the temperature 
was 5
o
C
 
then it rose in the middle of the distribution to 6
o
C
 
and was kept between 5 – 6oC till 
the end of the last sample and the time was about four hours. The temperature in round three 
started with 4
o
C
 
and increased in the last hour to reach 5
o
C
 
at the end of the distribution, while 
the time was about four hours. In Hebron the temperature of the box in round one was 3
o
C
 
at 
the beginning of the distribution; then the temperature decreased under the effect of the ice to 
2
o
C,
 
rose again to 3
o
C
 
and was stable to the end of the sample distribution.  
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The time from the beginning of the distribution to the end was about three hours. In round 
two, the temperature was 4
o
C
 
from the beginning of the distribution to the end of the 
distribution. The time was less than four hours. The temperature in round three started with 
3
o
C
 
and rose with time up to 7
o
C
 
in some points, and by the end of the distribution it was 6
o
C
 
while time was less than three hours. Further detailed results are shown in appendix B. 
 
2.6. Methods used in this study. 
 
The method that has been used in this study was the consensus mean method. Samples of the 
same material are sent to a large number of laboratories where requested tests are performed. 
Then the participant medical laboratories sent back their results to be analyzed and interpreted 
using the DI method. The consensus method for the participating medical laboratories was 
used to analyze the results of the laboratories. 
 
The Mean ( xˉ ) represents the arithmetic mean of test samples and the Standard Deviation 
(SD) was calculated using the following:     
     ˉ   
    
   Where; x = individual results xˉ = 
Mean n = total number of results. The data were then adjusted by excluding any values that 
are > ± 2SD from the mean. The mean and SD (now termed “weighted”) are then recalculated. 
For these calculations of SD to be meaningful, there must be at least 15 participants in a set, 
and at least half of the participant should have sufficiently good performance in comparison 
with each other to avoid having a weighted SD which is unhelpfully wide.  
 
DI is then calculated for each individual participant, it is also known as the Z- score. DI 
indicates the difference between the individual laboratory results and the weighted mean and 
can be used to compare the performance of a laboratory with that of other laboratories as well 
as with its own performance in previous surveys, and the formula is:  
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The DI score for any test has been interpreted depending on the UK-NEQAS classification 
(UK-NEQAS Quality Assurance in Haematology) as shown in Table 2.2:  
 
Table (2.2) Interpretation of the DI Scores 
The DI Result The Performance Abbreviation 
< 0.5 Excellent E 
0.5 – 1.0 Good G 
1.0 – 2.0 Satisfactory S 
2.0 – 3.0 Serious Error S.E 
 
The CV % and the clinical significance were calculated for all of the hematological 
parameters that were measured in this study. The CV % formula is shown below: 
     
            
           
      
The CV % was compared for evaluation of the three rounds using Chi-square for goodness-of-
fit and its formula is: 
      
                                   
              
  
 
Table (2.3) The limits of the Clinical Significance. 
The Hematological 
 Parameters values 
Limits  
Lowest limit (%)  Highest limit (%) 
WBCs - 8 %  of the value + 10 % of the value 
RBCs and Hgb - 3 % of the value + 4 % of the value 
Hct, MCV, MCH and MCHC - 4 % of the value  + 5 % of the value 
PLTs - 10 % of the value  + 15 % of the value 
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Chapter Three: Results 
 
 
3.1. Questionnaire results.  
 
In order to evaluate or study the quality control in the hematology laboratories in the West 
Bank – Palestine in the medical laboratories three cities were chosen for this study. The three 
cities chosen for this study are Nablus, Ramallah and Hebron representing the north, middle 
and south regions of West Bank. 
 
There are seventy nine medical laboratories in the study regions. These laboratories are 
distributed as follows: 31 in Nablus, 26 in Ramallah and 22 in Hebron. A questionnaire was 
sent to the seventy nine medical laboratories in the study regions between June and July 2010. 
The objective of the questionnaire was to collect basic information about the type of cell 
counters, work load and the IQC and EQAS measures implemented.  
 
However, only sixty laboratories accepted to participate in the study and filled the 
questionnaire. While eleven laboratories refused to participate in the study, five laboratories 
do not have an automated cell counter, two laboratories perform the CBC in other neighboring 
laboratories, and one laboratory performs the CBC manually.  
 
3.1.1. Analysis of the questionnaire data.  
 
In EQAS participation, it was found that fourty nine (81.7 %) of the participant medical 
laboratories do not run an EQAS in their laboratories, while only eleven medical laboratories 
(18.3 %) run an EQAS (Table 3.1.1).  
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Table (3.1.1) Distribution of the participating medical laboratories according to their participation in 
EQAS programs. Where n is the number of medical laboratories. 
 
Medical  
laboratory  
location 
Participation in an EQAS 
Yes No 
n % n % 
Nablus 2 18.0  19 38.8  
Ramallah 7 64.0  12 24.5  
Hebron 2 18.0  18 36.7  
Total  11 100  49 100 
  
3.1.2. The types of cell counters available at the participants' medical laboratories.  
 
The participant laboratories have different brands as well as different versions of cell counters. 
The most commonly used cell counter was CellDyn and it was available in 23 (38.3%) 
laboratories (Table 3.1.2). The second most commonly cell counter is Medonic followed by 
Sysmex, while other cell counters are used in a few laboratories (Table 3.1.2). 
 
Table (3.1.2) Types of cell counters used in the participant medical laboratories. Where n is the 
number of medical laboratories. 
 
Type of the  
machine 
Nablus Ramallah Hebron Total  
n % n % n % n % 
CellDyn 5 23.8  10 52.6  8 40.0  23 38.3  
Medonic 9 42.8 1 5.2  3 15.0  13 21.7  
Sysmex 3 14.3  3 15.8 2 10.0  8 13.3  
Celtac  1 4.7  3 15.8 3 15.0  7 11.7  
Coulter 1 4.7  1 5.3  2 10.0  4 6.7  
Advia  1 4.7  1 5.3  0 0.0 2 3.3  
ERMA 0 0.0   0 0.0  2 10.0  2 3.3  
Micros 1 4.7  0 0.0 0 0.0 1 1.7  
Total  21 100  19 100 20 100  60 100  
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3.1.3. IQC in participant medical laboratories.  
 
The implementation of IQC measure at the laboratory starts with the use of a blood calibrator 
designed for calibration of the specific cell counter as indicated by the manufacturer. Among 
our study sample, fifty six medical laboratories reported that they use the blood calibrator 
regularly; compared to four laboratories that do not use the blood calibrator (Table 3.1.3). The 
four laboratories that do not use a calibrator, they use samples from the previous day to check 
for the precision of the cell counter. 
 
Table (3.1.3) Distribution of participant laboratories according to use of blood calibrators, range of 
calibrator used and laboratory location. L, N and H refer to Low, Normal and High whole blood 
calibrators. Where n is the number of medical laboratories. 
 
 
Laboratory 
location 
No. of labs using blood calibrators  
Do not use blood 
calibrator 
Total 
 labs  
L, N & H blood 
calibrators 
N Blood  
calibrator 
n % n % n % n % 
Nablus 19 34.0  4 25.0  15 37.5  2 50.0  
Ramallah 19 34.0  9 56.0  10 25.0  0 0.0  
Hebron 18 32.0  3 19.0  15 37.5  2 50.0  
Total 56 100  16 100  40 100  4 100  
 
3.1.4. Frequency of cell counters calibration using certified whole blood calibrators.  
 
Table 3.1.4A shows the frequency of calibrator use in the three cities: Nablus, Ramallah and 
Hebron. Sixty four percent of the laboratories run the calibrator daily while, 11.0 % twice per 
week, 16.0 % once per week and 9.0 % of medical laboratories do it occasionally. 
 
Among the 56 laboratories that use the blood calibrator, 16 medical laboratories use low, 
normal and high blood calibrators while 40 laboratories use only the normal blood calibrator 
(Table 3.1.4B).  
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Table (3.1.4A) Frequency of cell counter calibration using certified whole blood calibrators in 
participant laboratories according to the city. Where n is the number of medical laboratories. 
 
 
Frequency of use of  
blood calibrator  
 
Nablus 
 
Ramallah 
 
 
Hebron 
 
 
Total  
N % n % n % n % 
Daily 11 58.0 18 95.0  7 39.0  36 64.0  
Twice per week 2 10.5  0 0.0  4 22.0  6 11.0  
Once per week 2 10.5  0 0.0  7 39.0   9 16.0  
Occasional 4 21.0  1 5.0  0 0.0  5 9.0  
Total  19 100  19 100  18 100  56 100  
 
 
Table (3.1.4B) Frequency of cell counter calibration using certified whole blood calibrators in 
participant laboratories according to the type of calibrator. Where n is the number of medical 
laboratories. 
 
Frequency of use of 
blood calibrator 
L, N & H  
blood calibrator 
N  
blood calibrator 
 
Total  
N % n % n % 
Daily 16 100  20 50.0  36 64.0  
Twice per week 0 0.0  6 15.0  6 11.0  
Once per week 0 0.0  9 22.5  9 16.0  
Occasional 0 0.0 5 12.5  5 9.0  
Total  16 100  40 100  56 100  
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3.2. Complete blood count results.  
 
There is a wide range of cell counters available in the Palestinian market. They represent a 
selection of many international trademarks. In this study, blood samples collected from 
healthy volunteers were aliquoted and distributed to the participant laboratories at three times 
or rounds, each separated from the previous one by around three weeks.  
 
The CBC results collected at each round were analyzed for the consensus mean. The 
consensus mean was then used as a reference for evaluating the performance of participant 
laboratories based on calculation of the DI. For calculation of the consensus mean  xˉ and the 
SD, the data were adjusted by excluding any values that deviate more than > 2SD from the 
mean. After exclusion, the mean and SD were recalculated and termed “weighted mean and 
SD” for all participating medical laboratories.  
 
When participating medical laboratories send back their results to be analyzed and interpreted 
using the consensus mean method and the DI method, the performance of the laboratories was 
evaluated. Unfortunately, the harmony of the CBC results was poor in general since there was 
a large difference between the hematologic parameters values recorded before and after the 
exclusion of the outlier medical laboratories.  
 
Tables 3.2A and 3.2B show the recorded lowest (LV) and highest (HV) values for each of the 
hematological parameters studied at each round of the study. The difference between the LV 
and HV reflects a wide variation in the results reported by the participant laboratories even 
after exclusion of outlier laboratories. Further detailed information of each parameter is shown 
in appendix C. 
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Table (3.2A) The lowest and highest hematologic parameters values recorded during the study before 
the exclusion of the outlier medical laboratories. 
 
Key: LV: Lowest Value, HV: Highest Value, Diff: Difference. 
Laboratory 
Parameters / unit 
Round One Round Two Round Three 
LV HV Diff LV HV Diff LV HV Diff 
WBCs  K / L 3.7 6.7 3.0 5.1 7.1 2.0 5.7 8.5 2.8 
RBCs  mill/L 4.4 6.7 2.3 4.3 6.9 2.6 3.9 6.4 2.4 
Hgb  g / dL 11.5 17.9 6.4 12.9 19.4 6.5 12.5 19.0 6.5 
Hct  % 34.1 55.8 21.7 35.4 82.1 46.7 33.6 56.6 23.0 
MCV fL 72.2 87.3 15.1 79.8 159.4 79.6 80.0 95.8 15.8 
MCH pg 23.9 34.8 10.9 26.2 30.8 4.6 25.2 32.3 7.1 
MCHC % 30.4 35.4 5.0 18.1 36.6 18.5 30.0 37.2 7.2 
PLTS K / L 173.0 349.0 176.0 120.0 298.0 178.0 168.0 297.0 129.0 
RDW % 10.3 16.9 6.6 9.4 16.0 6.6 10.0 17.6 7.6 
 
Table (3.2B) The lowest and highest hematologic parameters values recorded during the study after 
the exclusion of the outlier medical laboratories. 
 
Key: LV: Lowest Value, HV: Highest Value, Diff: Difference. 
Laboratory 
Parameters / unit 
Round One Round Two Round Three 
LV HV Diff LV HV Diff LV HV Diff 
WBCs K / L 4.9 6.3 1.4 5.2 6.4 1.2 6.1 7.8 1.7 
RBCs mill/L 5.7 6.7 1.0 4.9 5.6 0.7 4.9 5.7 0.8 
Hgb g / dL 14.9 17.9 3.0 13.4 16.0 2.6 14.5 17.3 2.8 
Hct % 44.2 55.8 11.6 35.4 48.7 13.3 44.0 53.0 9.0 
MCV fL 75.2 84.1 8.9 79.8 91.2 11.4 85.1 93.0 7.9 
MCH pg 23.9 27.7 3.8 26.7 30.3 3.6 27.7 32.0 4.3 
MCHC % 30.5 34.8 4.3 30.9 36.6 5.7 31.7 35.7 4.0 
PLTS K / L 208.0 327.0 119.0 165.0 276.0 111.0 184.0 291.0 107.0 
RDW % 11.5 15.1 3.6 11.2 14.8 3.6 10.9 14.6 3.7 
 34 
 
3.2.1. Statistical analysis of the CBC results. 
 
The results of the CBC were analyzed and interpreted using the consensus mean method and 
the DI method. The mean, SD were calculated, and then the weighted mean and weighted SD 
were recalculated after excluding the outlier laboratories and used to calculate the DI which 
evaluates the performance of the medical laboratories. The CV % for each parameter after 
trimming of the outlier medical laboratories was calculated in all rounds and was found >2 % 
implying poor performance. The CV % for each parameter was tested by Chi-square for 
goodness-of-fit to compare the performance of medical laboratories in the three rounds and 
assess if there is an improvement in their performance. It was found that their performance 
was the same in the three rounds (P > 0.05) implying no improvement for all parameters 
(Table 3.2.1D). Furthermore, their performance was assessed by calculating the clinical 
significance among the participating laboratories (S M Lewis, 2006). It was found that there 
were many laboratories outside the allowable limits even though the laboratories with 
performance > mean ± 2 SD were already excluded. The variability was at most in RBCs and 
Hgb and the least was in WBCs (Table 3.2.1C). 
 
Table 3.2.1A shows the values of each of the mean and weighted mean, SD and the wighted 
SD in addition to the CV % values recorded throughout the study. While table 3.2.1B2 shows 
the general performance of the medical laboratories and the numbers of the total medical 
laboratories after the exclusion of the outlier values in round one, two and three. To evaluate 
the CBC results, the DI and the CV % made the basic tools for evaluation. The calculation of 
DI and the CV % was done for each hematological parameter. The DI represent the deviation 
of the individual values from the consensus (or weighted) mean. But the CV % is a measure 
of the reproducibility. The interpretation of the DI was set into four categories; excellent, 
good, satisfactory, and serious error as shown in Table 3.2.1B1. The interpretation of the CV 
% results depends on the increase or decrease of its value. An increase in the CV % value 
indicates an increase in variability (less reproducibility), while a decrease in the CV % value 
was considered as an improvement in variability or reproducibility. However, a CV % > 2 % 
indicates in general poor performance or poor reproducibility. 
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Table (3.2.1A) Mean, SD and Coefficient of Variation of the CBC parameters in all rounds. 
CBC  
Parameter 
Round  
No. 
 
Mean 
Weighted 
Mean 
 
SD 
Weighted 
SD 
 
CV % 
 
WBCs 
 
1 5.5 5.5 0.47 0.36 6.7  
2 5.9 5.8 0.39 0.29 5.1  
3 6.9 6.9 0.50 0.36 5.2  
 
RBCs 
1 6.2 6.3 0.32 0.22 3.6  
2 5.2 5.2 0.35 0.16 3.2  
3 5.4 5.4 0.33 0.18 3.4  
 
Hgb 
1 16.4 16.4 0.86 0.58 3.6  
2 14.9 14.7 0.99 0.46 3.2  
3 15.9 16.0 0.87 0.51 3.3  
 
 
Hct 
 
1 49.8 50.0 3.12 2.37 4.7  
2 44.9 43.7 5.93 1.90 4.4  
3 47.8 48.0 3.03 1.92 4.0  
 
 
MCV 
 
1 79.6 79.4 2.92 2.28 2.9  
2 85.8 84.5 10.00 2.54 3.0  
3 88.8 88.8 2.69 2.06 2.3  
 
 
MCH 
 
 
1 26.3 26.2 1.41 0.87 3.6  
2 28.5 28.5 0.97 0.82 2.9  
3 29.7 29.7 1.19 0.89 3.0  
 
 
MCHC 
1 32.9 32.8 1.19 1.04 3.2  
2 33.5 33.7 2.35 1.20 3.6  
3 33.4 33.4 1.33 0.98 2.9  
 
 
PLTs 
 
1 269.3 269.5 33.00 29.20 10.8   
2 211.8 214.8 32.80 24.99 11.6   
3 238.5 238.7 27.45 25.30 10.6  
 
RDW 
 
1 13.4 5.5 1.20 0.87 6.6  
2 13.1 5.8 1.15 0.87 6.6  
3 13.2 6.9 1.23 0.87 6.6  
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Table (3.2.1B1) The performance of participating medical laboratories in all rounds after excluding 
outlier values in percentage. Key: E: Excellent (≤ 0.5 SD), G: Good (0.5-1 SD), S: Satisfactory (1-2 
SD), and SE: Serious Error (≥ 2SD). 
 
 
CBC 
 Parameters 
 
Round 
No. 
Performance (%) Participating Medical Laboratories (%) 
E 
% 
G 
% 
S 
% 
SE 
% 
Labs  
Included % 
Labs  
Excluded %  
Total 
 Labs % 
WBCs 1 33.3 23.3 36.7 1.7 95.0 5.0 100  
RBCs 1 43.3 26.6 23.3 5.1 98.3 1.7 100  
Hgb 1 40.0 30.0 25.0 3.3 98.3 1.7  100  
Hct 1 43.3 31.7 18.3 5.0 98.3 1.7  100  
MCV 1 25.0 38.3 26.7 3.3 93.3 6.7  100  
MCH 1 38.3 25.0 31.7 3.3 98.3 1.7  100  
MCHC 1 28.3 28.3 35.0 1.7 93.3 1.7   100  
PLTs 1 31.7 28.3 35.0 1.7 96.7 3.3  100  
RDW 1 30.0 36.7 23.3 1.7 91.7 8.3  100  
WBCs 2 33.8 25.5 30.5 1.7 91.5 8.5  100  
RBCs 2 40.7 28.9 22.0 3.4 95.0 5.0  100  
Hgb 2 51.0 17.0 22.0 5.0 95.0 5.0  100  
Hct 2 39.0 40.7 11.9 3.4 95.0 5.0  100  
MCV 2 35.6 34.0 20.3 5.1 98.3 1.7  100  
MCH 2 35.6 22.0 30.5 5.1 93.2 6.7  100  
MCHC 2 37.3 30.5 23.7 6.8 98.3 1.7  100  
PLTs 2 40.7 22.0 27.1 3.4 93.2 6.7  100  
RDW 2 42.4 20.3 27.1 3.4 93.2 6.7  100  
WBCs 3 31.6 31.6 22.8 3.5 89.5 10.5  100  
RBCs 3 40.5 21.0 26.3 5.3 93.1 6.9  100  
Hgb 3 42.1 31.6 14.0 7.0 94.7 5.3  100  
Hct 3 33.3 19.3 36.8 5.3 94.7 5.3  100  
MCV 3 28 26.3 36.8 2.0 93.1 6.9  100  
MCH 3 35.0 28.1 24.7 5.3 93.1 6.9  100  
MCHC 3 35.0 24.6 28.1 3.5 91.2 8.8 100  
PLTs 3 40.4 24.5 28.1 3.5 96.5 3.5  100  
RDW 3 28.1 33.3 28.1 1.7 91.2 8.8  100  
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Table (3.2.1B2) The performance of participating medical laboratories in all rounds after excluding 
outlier values. Key: E: Excellent (≤ 0.5 SD), G: Good (0.5-1 SD), S: Satisfactory (1-2 SD), and SE: 
Serious Error (≥ 2SD). Where n is the number of medical laboratories. 
 
 
CBC 
 Parameters 
 
Round 
No. 
Performance (n) Participating Medical Laboratories (n) 
 
E 
 
G 
 
S 
 
SE 
Labs  
Included 
Labs  
Excluded 
Total 
 Labs 
WBCs 1 20 14 22 1 57 3 60 
RBCs 1 26 16 14 3 59 1 60 
Hgb 1 24 18 15 2 59 1 60 
Hct 1 26 19 11 3 59 1 60 
MCV 1 15 23 16 2 56 4 60 
MCH 1 23 15 19 2 59 1 60 
MCHC 1 17 17 21 1 56 1 60 
PLTs 1 19 17 21 1 58 2 60 
RDW 1 18 22 14 1 55 5 60 
WBCs 2 20 15 18 1 54 5 59 
RBCs 2 24 17 13 2 56 3 59 
Hgb 2 30 10 13 3 56 3 59 
Hct 2 23 24 7 2 56 3 59 
MCV 2 21 22 12 3 58 1 59 
MCH 2 21 13 18 3 55 4 59 
MCHC 2 22 18 14 4 58 1 59 
PLTs 2 24 13 16 2 55 4 59 
RDW 2 25 12 16 2 55 4 59 
WBCs 3 18 18 13 2 51 6 57 
RBCs 3 23 12 15 3 53 4 57 
Hgb 3 24 18 8 4 54 3 57 
Hct 3 19 11 21 3 54 3 57 
MCV 3 16 15 21 1 53 4 57 
MCH 3 20 16 14 3 53 4 57 
MCHC 3 20 14 16 2 52 5 57 
PLTs 3 23 14 16 2 55 2 57 
RDW 3 16 19 16 1 52 5 57 
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Table (3.2.1C) Clinical Significance of CBC parameters obtained from participating medical 
laboratories. 
 
CBC  
Parameters 
 
 
(Limits of 
clinical 
Significance) 
 
 
Round 
No. 
 
 
No. of 
Labs 
Below 
lower 
limit  
 
 
 
No. of 
Labs 
above  
higher 
limit 
  
 
 
 
Weighted 
mean 
 
Range of clinical 
significance  
Total No. 
of Labs 
outsides 
the limits 
 
 
 
 
CV 
% 
the 
Lower 
limit 
the 
Higher 
limit 
 
n 
 
% 
 
 
       WBCs  
(8-10%) 
1 4 3 5.5 5.0 6.0 7 12  6.7  
2 5 1 5.8 5.3 6.4 6 11  5.1  
3 4 3 6.9 6.3 7.5 7 14  5.2  
 
RBCs 
 (3-4%) 
1 12 7 6.3 6.0 6.5 19 32  3.6  
2 9 6 5.2 5.0 5.4 15 27  3.2  
3 10 6 5.4 5.2 5.5 16 30 3.4  
 
Hgb  
(3-4%) 
 
1 11 9 16.4 15.9 17.1 20 34  3.6  
2 9 7 14.7 14.3 15.3 16 29  3.2  
3 7 7 16.0 15.5 16.6 14 26  3.3  
 
Hct 
(4-5%) 
1 9 9 50.0 48.0 52.5 18 30  4.7  
2 8 4 43.7 41.9 45.9 12 21  4.4  
3 11 6 48.0 46.1 50.4 17 31  4.0  
 
MCV 
(4-5%) 
 
1 5 3 79.4 76.2 83.3 8 14  2.9  
2 4 4 84.5 81.1 88.7 8 14  3.0  
3 2 0 88.8 85.3 93.3 2 4  2.3  
 
MCH 
(4-5%) 
 
1 5 7 26.2 25.1 27.5 12 20 3.6  
2 4 3 28.5 27.3 29.9 7 12  2.9  
3 3 3 29.7 28.5 31.2 6 12  3.0  
 
MCHC 
(4-5%) 
1 4 6 32.8 31.4 34.4 10 18  3.2  
2 6 5 33.7 32.3 35.4 11 19  3.6  
3 6 3 33.4 32.1 35.1 9 18  2.9  
 
Plts 
(10-15%) 
1 10 8 269.5 242.5 309.9 18 31  10.8  
2 11 5 214.8 193.3 247.0 16 29  11.6   
3 9 6 238.7 214.8 274.5 15 27 10.6  
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Table (3.2.1D) The Chi-square results for comparing the CV% of the CBC parameters. 
 
  
CBC  
Parameter 
 
P value 
CBC 
Parameter 
 
P value 
CBC 
Parameter 
 
P value 
WBCs P > 0.05  Hct P > 0.05  MCH P > 0.05  
RBCs P > 0.05  MCV P > 0.05  PLTs P > 0.05  
Hgb P > 0.05  MCHC P > 0.05  RDW P > 0.05  
 
 
3.2.2. Evaluation of the CBC results according to the frequency of cell counter 
calibration. 
 
The frequency of blood calibrator use was divided into four groups in this study; daily, twice 
per week, once per week and occasional. The evaluation of the CBC results show that the 
medical laboratories which run their blood calibrator on daily basis showed a better 
performance and more medical laboratories in this group showed also excellent performance 
based on DI (Table 3.2.2A).  
 
3.2.3. Evaluation of the CBC results According to the type of blood calibrator. 
 
Medical laboratories were divided into two groups based on their use of blood calibrators: 
those used only normal blood calibrator and those who use low, normal and high blood 
calibrators (Table 3.2.3A and B).  
 
3.2.4. Evaluation of the CBC results according to the type of cell counter. 
 
Eight types of cell counters were participated in this study, previously shown in table 3.1.2. 
The performance in each round for all hematological parameters was reported. Table 3.2.4 
shows the performance and the evaluation according to the cell counter type. 
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         Table (3.2.2A) Evaluation of CBC results in participant laboratories according to frequency of cell counter calibration in percentage. 
        Where n is the number of medical laboratories, AVG: Average percentage of the three rounds. 
 
 
 
CBC 
 
 
Round 
No. 
Frequency of blood calibrator use (%) 
Daily 
n = 36 
Twice per week 
n = 6 
Once per week 
n = 9 
Occasional 
n = 5 
E 
(%) 
G 
(%)  
S 
(%) 
SE 
(%) 
E 
(%) 
G 
(%)  
S 
(%) 
SE 
(%) 
E 
(%) 
G 
(%)  
S 
(%) 
SE 
(%) 
E 
(%) 
G 
(%)  
S 
(%) 
SE 
(%) 
 
WBCs 
1 37.1 34.3 28.6 0.0 40.0 0.0 60.0 0.0 22.0 11.0 56.0 11.0 50.0 0.0 50.0 0.0 
2 36.4 27.2 36.4 0.0 20.0 80.0 0.0 0.0 37.5 12.5 50.0 0.0 40.0 20.0 20.0 20.0 
3 43.8 34.4 18.7 3.1 33.3 33.3 33.4 0.0 22.2 44.5 33.3 0.0 20.0 20.0 40.0 20.0 
AVG 39.1 32.0 27.9 1.0 31.1 37.8 31.2 0.0 27.3 22.7 46.4 3.7 36.7 13.3 36.7 13.3 
 
RBCs 
1 41.7 25.0 30.6 2.7 33.3 33.3 16.7 16.7 55.5 22.3 11.1 11.1 50.0 25.0 25.0 0.0 
2 38.2 35.3 26.5 0.0 16.7 33.3 33.3 16.7 75.0 25 0.0 0.0 50.0 25.0 0.0 25.0 
3 55.9 23.5 14.7 5.9 0.0 0.0 100.0 0.0 33.4 33.3 33.3 0.0 0.0 0.0 75.0 25.0 
AVG 45.3 27.9 23.9 2.9 16.7 22.2 50.0 11.4 54.6 26.8 14.8 3.7 33.3 16.7 33.3 16.7 
 
Hgb 
1 41.7 27.8 30.5 0.0 0.0 50.0 50.0 0.0 33.3 44.5 11.1 11.1 75.0 25.0 0.0 0.0 
2 58.8 14.7 20.6 5.9 0.0 33.3 50.0 16.7 50.0 25.0 25.0 0.0 75.0 0.0 25.0 0.0 
3 47.1 35.3 8.8 8.8 0.0 25.0 50.0 25.0 44.4 44.4 11.2 0.0 50.0 25.0 25.0 0.0 
AVG 49.2 25.9 59.9 4.9 0.0 36.1 50.0 13.9 42.6 38.0 15.8 3.7 8.0 2.0 2.0 0.0 
 
Hct 
1 44.4 33.3 22.3 0.0 33.3 16.7 16.7 33.3 44.4 44.4 0.0 11.2 50.0 50.0 0.0 0.0 
2 38.3 44.1 17.6 0.0 50.0 16.7 16.7 16.6 42.8 57.2 0..0 0.0 40.0 40.0 0.0 20.0 
3 38.3 20.5 38.3 2.9 0.0 0.0 100.0 0.0 44.4 22.3 33.3 0.0 25.0 50.0 0.0 25.0 
AVG 40.3 32.6 26.1 0.9 27.8 11.2 44.5 16.6 43.9 41.6 11.1 3.7 38.3 46.7 0.0 15.0 
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        Table (3.2.2A) Continued.  
 
 
 
CBC  
 
Round 
No. 
Frequency of blood calibrator use (%) 
Daily 
n = 36 
Twice per week 
n = 6 
Once per week 
n = 9 
Occasional 
n = 5 
E 
% 
G 
% 
S 
% 
SE 
% 
E  
(%) 
G 
(%)  
S 
(%) 
SE 
(%) 
E 
 (%) 
G 
(%)  
S 
(%) 
SE 
(%) 
E  
(%) 
G 
(%)  
S 
(%) 
SE 
(%) 
 
MCV 
1 29.4 41.2 26.5 2.9 40.0 40.0 0.0 20.0 11.2 44.4 44.4 0.0 25.0 50.0 25.0 0.0 
2 40.0 34.3 20.0 5.7 16.7 50.0 16.6 16.7 50.0 37.5 12.5 0.0 20.0 40.0 40.0 0.0 
3 41.2 20.6 35.3 2.9 0.0 75.0 25.0 0.0 12.5 37.5 50.0 0.0 20.0 20.0 60.0 0.0 
AVG 36.9 32.0 27.3 3.8 18.9 55.0 13.9 12.3 24.6 39.8 35.6 0.0 21.7 36.7 41.7 0.0 
 
MCH 
1 47.2 22.2 27.8 2.8 16.7 33.3 50.0 0.0 25.0 25.0 50.0 0.0 40.0 20.0 40.0 0.0 
2 29.4 26.5 41.2 2.9 50.0 0.0 0.0 50.0 66.7 11.1 22.2 0.0 50.0 25.0 25.0 0.0 
3 38.2 32.4 29.4 0.0 100.0 0.0 0.0 0.0 33.4 44.4 22.2 0.0 20.0 20.0 0.0 60.0 
AVG 38.3 27.0 32.8 1.9 55.6 11.1 16.7 16.7 41.7 26.8 31.5 0.0 36.7 21.7 21.7 20.0 
 
MCHC 
1 31.5 22.8 45.7 0.0 0.0 60.0 20.0 20.0 37.5 37.5 25.0 0.0 25.0 50.0 25.0 0.0 
2 45.7 22.8 28.6 2.9 16.7 50.0 0.0 33.3 37.5 37.5 25.0 0.0 40.0 20.0 20.0 20.0 
3 44.1 20.6 32.4 2.9 25.0 25.0 25.0 25.0 33.3 33.3 33.4 0.0 0.0 66.7 33.3 0.0 
AVG 40.4 22.1 35.6 1.9 13.9 45.0 15.0 26.1 36.1 36.1 27.8 0.0 21.7 45.6 26.1 6.7 
 
Plts 
1 34.3 22.8 40.0 2.9 50.0 16.7 33.3 0.0 33.3 55.5 11.2 0.0 20.0 40.0 40.0 0.0 
2 47.0 20.6 29.4 3.0 33.4 33.3 33.3 0.0 42.8 42.8 14.4 0.0 25.0 25.0 50.0 0.0 
3 40.0 25.7 31.4 2.9 60.0 20.0 20.0 0.0 55.6 22.2 22.2 0.0 25.0 50.0 25.0 0.0 
AVG 40.4 23.0 33.6 2.9 47.8 23.3 28.8 0.0 43.9 40.2 15.9 0.0 23.3 38.3 38.3 0.0 
 
RDW 
1 36.4 33.3 27.3 3.0 16.7 33.3 50.0 0.0 33.3 44.4 22.3 0.0 0.0 100.0 0.0 0.0 
2 41.2 26.5 32.3 0.0 16.7 16.7 33.3 16.7 66.6 11.2 22.2 0.0 0.0 33.3 33.4 33.3 
3 38.2 32.4 29.4 0.0 25.0 0.0 50.0 25.0 22.3 44.4 33.3 0.0 0.0 66.7 33.3 0.0 
AVG 38.6 30.7 29.7 1.0 19.4 16.7 44.4 13.9 40.7 33.3 25.9 0.0 0.0 66.7 22.3 11.1 
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Table (3.2.2B) Evaluation of CBC results in participant laboratories according to frequency of cell 
counter calibration. Where n is the number of medical laboratories, AVG: Average of the three rounds. 
 
 
CBC  
 
R 
 
No. 
Frequency of blood calibrator use 
Daily  
n = 36 
Twice per week  
n = 6  
Once per week 
n = 9 
Occasional 
n = 5 
E G S SE E G S SE E G S SE E G S SE 
 
WBCs 
1 13.0 12.0 10.0 0.0 2.0 0.0 3.0 0.0 2.0 1.0 5.0 1.0 2.0 0.0 2.0 0.0 
2 12.0 9.0 12.0 0.0 1.0 4.0 0.0 0.0 3.0 1.0 4.0 0.0 2.0 1.0 1.0 1.0 
3 14.0 11.0 6.0 1.0 1.0 1.0 1.0 0.0 2.0 4.0 3.0 0.0 1.0 1.0 2.0 1.0 
AVG 13.0 10.7 9.3 0.3 1.3 1.6 1.3 0.0 2.3 2.0 4.0 0.3 1.7 0.6 1.7 0.6 
 
RBCs 
1 15.0 9.0 11.0 1.0 2.0 2.0 1.0 1.0 5.0 2.0 1.0 1.0 2.0 1.0 1.0 0.0 
2 13.0 12.0 9.0 0.0 1.0 2.0 2.0 1.0 6.0 2.0 0.0 0.0 2.0 1.0 0.0 1.0 
3 19.0 8.0 5.0 2.0 0.0 0.0 4.0 0.0 3.0 3.0 3.0 0.0 0.0 0.0 3.0 1.0 
AVG 15.7 9.7 8.3 1.0 1.0 1.3 2.3 0.6 4.7 2.3 1.3 0.3 1.3 0.6 1.3 0.6 
 
Hgb 
1 15.0 10.0 11.0 0.0 0.0 3.0 3.0 0.0 3.0 4.0 1.0 1.0 3.0 1.0 0.0 0.0 
2 20.0 5.0 7.0 2.0 0.0 2.0 3.0 1.0 4.0 2.0 2.0 0.0 3.0 0.0 1.0 0.0 
3 16.0 12.0 3.0 3.0 0.0 1.0 2.0 1.0 4.0 4.0 1.0 0.0 2.0 1.0 1.0 0.0 
AVG 17.0 9.0 7.0 1.7 0.0 2.0 2.7 0.6 3.7 3.3 1.3 0.3 2.7 0.6 0.6 0.0 
 
Hct 
1 16.0 12.0 8.0 0.0 2.0 1.0 1.0 2.0 4.0 4.0 0.0 1.0 2.0 2.0 0.0 0.0 
2 13.0 15.0 6.0 0.0 3.0 1.0 1.0 1.0 3.0 4.0 0.0 0.0 2.0 2.0 0.0 1.0 
3 13.0 7.0 13.0 1.0 0.0 0.0 4.0 0.0 4.0 2.0 3.0 0.0 1.0 2.0 0.0 1.0 
AVG 14.0 11.3 9.0 0.3 1.7 0.6 2.0 1.0 3.7 3.3 1.0 0.3 1.7 2.0 0.0 0.6 
 
MCV 
1 10.0 14.0 9.0 1.0 2.0 2.0 0.0 1.0 1.0 4.0 4.0 0.0 1.0 2.0 1.0 0.0 
2 14.0 12.0 7.0 2.0 1.0 3.0 1.0 1.0 4.0 3.0 1.0 0.0 1.0 2.0 2.0 0.0 
3 14.0 7.0 12.0 1.0 0.0 3.0 1.0 0.0 1.0 3.0 4.0 0.0 1.0 1.0 3.0 0.0 
AVG 12.7 11.0 9.3 1.3 1.0 2.7 0.6 0.6 2.0 3.3 3.0 0.0 1.0 1.7 2.0 0.0 
 
MCH 
1 17.0 8.0 10.0 1.0 1.0 2.0 3.0 0.0 2.0 2.0 4.0 0.0 2.0 1.0 2.0 0.0 
2 10.0 9.0 14.0 1.0 2.0 0.0 0.0 2.0 6.0 1.0 2.0 0.0 2.0 1.0 1.0 0.0 
3 13.0 11.0 10.0 0.0 3.0 0.0 0.0 0.0 3.0 4.0 2.0 0.0 1.0 1.0 0.0 3.0 
AVG 13.3 9.3 11.3 0.6 2.0 0.6 1.0 0.6 3.7 2.3 2.7 0.0 1.7 1.0 1.0 1.0 
 
MCHC 
1 11.0 8.0 16.0 0.0 0.0 3.0 1.0 1.0 3.0 3.0 2.0 0.0 1.0 2.0 1.0 0.0 
2 16.0 8.0 10.0 1.0 1.0 3.0 0.0 2.0 3.0 3.0 2.0 0.0 2.0 1.0 1.0 1.0 
3 15.0 7.0 11.0 1.0 1.0 1.0 1.0 1.0 3.0 3.0 3.0 0.0 0.0 2.0 1.0 0.0 
AVG 14.0 7.7 12.3 0.6 0.6 2.3 0.6 1.3 3.0 3.0 2.3 0.0 1.0 1.7 1.0 0.3 
 
Plts 
1 12.0 8.0 14.0 1.0 3.0 1.0 2.0 0.0 3.0 5.0 1.0 0.0 1.0 2.0 2.0 0.0 
2 16.0 7.0 10.0 1.0 2.0 2.0 2.0 0.0 3.0 3.0 1.0 0.0 1.0 1.0 2.0 0.0 
3 14.0 9.0 11.0 1.0 3.0 1.0 1.0 0.0 5.0 2.0 2.0 0.0 1.0 2.0 1.0 0.0 
AVG 14.0 8.0 11.7 1.0 2.7 1.3 1.7 0.0 3.7 3.3 1.3 0.0 1.0 1.7 1.7 0.0 
 
RDW 
1 12.0 11.0 9.0 1.0 1.0 2.0 3.0 0.0 3.0 4.0 2.0 0.0 0.0 3.0 0.0 0.0 
2 14.0 9.0 11.0 0.0 2.0 1.0 2.0 1.0 6.0 1.0 2.0 0.0 0.0 1.0 1.0 1.0 
3 13.0 11.0 10.0 0.0 1.0 0.0 2.0 1.0 2.0 4.0 3.0 0.0 0.0 2.0 1.0 0.0 
AVG 13.0 10.3 10.0 0.3 1.3 1.0 2.3 0.6 3.7 3.0 2.3 0.0 0.0 2.0 0.6 0.3 
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Table (3.2.3A) Evaluation of CBC results from participant medical laboratories according to the type of blood calibrator used in percentage. 
Where n is the number of medical laboratories, AVG: Average percentage of the three rounds. 
 
 
CBC  
parameter 
 
Round 
No. 
Type of blood calibrator use (%) 
L, N & H 
n = 16 
N 
n = 40  
E % G % S % SE % E % G % S % SE %  
 
WBCs 
1 26.7 33.3 33.3 6.7 39.5 21.0 39.5 0.0 
2 54.0 23.0 23.0 0.0 29.0 31.6 36.8 2.6 
3 46.7 20.0 33.3 0.0 32.3 41.2 20.6 5.9 
AVG 42.5 25.4 29.9 2.2 33.6 31.3 32.3 2.8 
 
RBCs 
1 37.5 25.0 31.2 6.3 46.3 25.6 23.0 5.1 
2 46.7 40.0 13.3 0.0 40.6 29.7 24.3 5.4 
3 62.5 18.7 12.5 6.3 34.3 22.9 37.1 5.7 
AVG 48.9 27.9 19.0 4.2 40.4 22.1 28.2 5.4 
 
Hgb 
1 31.3 37.5 31.2 0.0 41.0 30.7 25.7 2.6 
2 40.0 13.3 33.4 13.3 56.7 19.0 21.6 2.7 
3 37.5 37.5 12.5 12.5 45.7 34.3 14.3 5.7 
AVG 36.3 29.4 25.7 8.6 47.8 28.0 20.5 3.7 
 
Hct 
1 31.3 50.0 18.7 0.0 48.7 23.0 20.6 7.7 
2 33.3 53.4 13.3 0.0 43.3 37.8 13.5 5.4 
3 56.3 18.7 18.7 6.3 30.0 10.0 56.7 3.3 
AVG 40.3 40.7 16.9 2.1 40.7 23.6 30.3 5.5 
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Table (3.2.3A) Continued.  
 
 
CBC  
parameter 
 
Round  
No. 
Type of blood calibrator use (%) 
L, N & H 
n = 16 
N 
n = 40  
E G S SE E G S SE 
 
MCV 
1 43.7 43.7 12.6 0.0 19.4 41.6 33.4 5.6 
2 60.0 26.7 13.3 0.0 28.2 41.0 23.1 7.7 
3 50.0 31.5 18.7 0.0 22.8 25.7 48.6 2.9 
AVG 51.3 34.0 14.9 0.0 23.5 36.0 35.0 5.4 
 
MCH 
1 37.5 43.8 18.7 0.0 41.0 15.4 41.0 2.6 
2 28.6 21.4 50.0 0.0 43.3 21.6 27.0 8.1 
3 40.0 40.0 20.0 0.0 38.9 27.8 25.0 8.3 
AVG 35.4 35.1 29.6 0.0 41.1 21.6 31.0 6.3 
 
MCHC 
1 31.2 12.5 56.3 0.0 27.8 38.9 30.5 2.8 
2 46.7 13.3 33.3 6.7 35.9 33.3 23.1 7.7 
3 26.7 26.7 40.0 6.6 38.9 27.8 25.0 8.3 
AVG 34.9 17.5 43.2 4.4 34.2 33.2 26.2 6.3 
 
Plts 
1 33.3 26.7 40.0 0.0 33.3 30.8 33.3 2.6 
2 50.0 21.4 21.4 7.2 40.5 27.0 32.5 0.0 
3 50.0 12.5 31.2 6.3 37.8 32.4 29.7 0.0 
AVG 44.4 20.2 30.9 4.5 37.2 30.1 31.8 0.9 
 
RDW 
1 31.2 43.8 25.0 0.0 31.4 37.1 28.6 2.9 
2 40.0 26.7 33.3 0.0 43.3 21.6 29.7 5.4 
3 37.5 37.5 25.0 0.0 29.4 32.3 35.3 3.0 
AVG 36.2 36.0 27.8 0.0 34.7 30.3 31.2 3.7 
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Table (3.2.3B) Evaluation of CBC results from participant medical laboratories according to the type 
of blood calibrator used. Where n is the number of medical laboratories, AVG: Average of the three 
rounds. 
 
CBC  
 
Round No. 
Type of blood calibrator use 
L, N & H 
n = 16 
N 
n = 40  
E G S SE E G S SE 
 
WBCs 
1 4.0 5.0 5.0 1.0 15.0 8.0 15.0 0.0 
2 7.0 3.0 3.0 0.0 11.0 12.0 14.0 1.0 
3 7.0 3.0 5.0 0.0 11.0 14.0 7.0 2.0 
Average 6.0 3.7 4.3 0.3 12.3 11.3 12.0 1.0 
 
RBCs 
1 6.0 4.0 5.0 1.0 18.0 10.0 9.0 2.0 
2 7.0 6.0 2.0 0.0 15.0 11.0 9.0 2.0 
3 10.0 3.0 2.0 1.0 12.0 8.0 13.0 2.0 
Average 7.7 4.3 3.0 0.6 15.0 9.7 10.3 2.0 
 
Hgb 
1 5.0 6.0 5.0 0.0 16.0 12.0 10.0 1.0 
2 6.0 2.0 5.0 2.0 21.0 7.0 8.0 1.0 
3 6.0 6.0 2.0 2.0 16.0 12.0 5.0 2.0 
Average 5.7 4.7 4.0 1.3 17.7 10.3 7.7 1.3 
 
Hct 
1 5.0 8.0 3.0 0.0 19.0 9.0 8.0 3.0 
2 5.0 8.0 2.0 0.0 16.0 14.0 5.0 2.0 
3 9.0 3.0 3.0 1.0 9.0 3.0 17.0 1.0 
Average 6.3 6.3 2.7 0.3 14.7 8.7 10.0 2.0 
 
MCV 
1 7.0 7.0 2.0 0.0 7.0 15.0 12.0 2.0 
2 9.0 4.0 2.0 0.0 11.0 16.0 9.0 3.0 
3 8.0 5.0 3.0 0.0 8.0 9.0 17.0 1.0 
Average 8.0 5.3 2.3 0.0 8.7 13.3 12.7 2.0 
 
MCH 
1 6.0 7.0 3.0 0.0 16.0 6.0 16.0 1.0 
2 4.0 3.0 7.0 0.0 16.0 8.0 10.0 3.0 
3 6.0 6.0 3.0 0.0 14.0 10.0 9.0 3.0 
Average 5.3 5.3 4.3 0.0 15.3 8.0 11.7 2.3 
 
MCHC 
1 5.0 2.0 9.0 0.0 10.0 14.0 11.0 1.0 
2 7.0 2.0 5.0 1.0 14.0 13.0 9.0 3.0 
3 4.0 4.0 6.0 1.0 14.0 10.0 9.0 3.0 
Average 5.3 2.7 6.7 0.6 12.7 12.3 9.6 2.3 
 
Plts 
1 5.0 4.0 6.0 0.0 13.0 12.0 13.0 1.0 
2 7.0 3.0 3.0 1.0 15.0 10.0 12.0 0.0 
3 8.0 2.0 5.0 1.0 14.0 12.0 11.0 0.0 
Average 6.7 3.0 4.7 0.6 14.0 11.3 12.0 0.3 
 
RDW 
1 5.0 7.0 4.0 0.0 11.0 13.0 10.0 1.0 
2 6.0 4.0 5.0 0.0 16.0 8.0 11.0 2.0 
3 6.0 6.0 4.0 0.0 10.0 11.0 12.0 1.0 
Average 5.7 5.7 4.3 0.0 12.3 10.7 11.0 1.3 
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Table (3.2.4) Evaluation of the CBC results according to the type of cell counter. Where n is the 
number of medical laboratories. 
 
 
CBC 
 
Round 
No. 
Cell counter  
CellDyn n = 23 Medonic n = 13  Sysmex n = 8 Celtac n = 7 
E G S SE E G S SE E G S SE E G S SE 
 
WBCs 
1 9 7 5 0 4 1 6 1 2 1 5 0 2 3 2 0 
2 9 8 3 0 3 5 3 1 6 1 1 0 2 1 4 0 
3 7 5 7 1 4 4 3 0 4 3 0 0 2 5 0 0 
Total 25 20 15 1 11 10 12 2 12 5 6 0 6 9 6 0 
 
RBCs 
1 8 6 5 3 5 3 5 0 3 4 1 0 5 0 2 0 
2 11 6 5 0 3 5 2 2 5 1 1 0 4 1 1 0 
3 9 5 5 1 2 1 7 2 3 3 1 0 2 3 1 0 
Total 28 17 15 4 10 9 14 4 11 8 3 0 11 4 4 0 
 
Hgb 
1 5 8 9 0 7 4 1 1 5 2 1 0 2 2 3 0 
2 8 3 9 2 8 1 2 1 4 2 1 0 3 2 1 0 
3 6 9 2 3 7 2 3 0 5 2 0 0 2 2 1 1 
Total 19 20 20 5 22 7 6 2 14 6 2 0 7 6 5 1 
 
Hct 
1 8 8 4 2 7 3 2 1 4 2 2 0 4 2 1 0 
2 11 9 2 0 6 5 0 2 2 4 1 0 1 2 2 0 
3 8 4 7 1 4 3 4 1 4 1 2 0 0 2 4 0 
Total 27 21 13 3 17 11 6 4 10 7 5 0 5 6 7 0 
 
MCV 
1 7 11 4 1 1 6 4 1 2 4 2 0 4 1 2 0 
2 11 9 2 0 2 5 6 0 3 3 2 0 2 3 0 1 
3 8 6 6 0 1 2 9 0 2 4 1 0 2 1 3 1 
Total 26 26 12 1 4 13 19 1 7 11 5 0 8 5 5 2 
 
MCH 
1 8 6 9 0 5 2 4 1 3 4 1 0 2 2 3 0 
2 5 6 7 2 7 0 5 0 3 4 1 0 4 1 2 0 
3 5 8 6 1 4 2 3 2 4 0 3 0 2 4 1 0 
Total 18 20 22 3 16 4 12 3 10 8 5 0 8 7 6 0 
 
MCHC 
1 7 6 8 0 3 5 3 1 4 1 3 0 1 3 3 0 
2 10 6 3 3 4 5 3 1 4 3 1 0 2 2 2 0 
3 5 4 9 2 3 3 5 0 1 5 1 0 5 1 1 0 
Total 22 16 20 5 10 13 11 2 9 9 5 0 8 6 6 0 
 
Plts 
1 8 4 9 0 3 5 5 0 4 3 1 0 2 1 4 0 
2 9 4 8 1 3 5 3 0 7 0 0 0 3 2 1 0 
3 8 1 11 1 3 5 4 0 4 2 1 0 3 3 1 0 
Total 25 9 28 2 9 15 12 0 15 5 2 0 8 6 6 0 
 
RDW 
1 8 11 4 0 3 4 3 0 2 4 2 0 2 1 2 1 
2 10 6 6 0 1 3 4 2 6 0 2 0 2 2 3 0 
3 9 8 5 0 1 4 3 1 1 3 3 0 2 1 4 0 
Total 27 25 15 0 5 11 10 3 9 7 7 0 6 4 9 1 
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Table (3.2.4) Continued. 
 
CBC 
 
Round 
No. 
Cell counter  
Coulter n = 4 Advia n = 2 ERMA n = 2 Micros n = 1 
E G S SE E G S SE E G S SE E G S SE 
 
WBCs 
1 1 1 2 0 1 0 1 0 0 1 1 0 1 0 0 0 
2 0 0 3 0 0 0 2 0 0 0 1 0 0 0 1 0 
3 1 1 1 0 0 0 1 1 0 0 1 0 0 0 0 0 
Total 2 2 6 0 1 0 4 1 0 1 3 0 1 0 1 0 
 
RBCs 
1 2 1 1 0 2 0 0 0 1 1 0 0 0 1 0 0 
2 0 2 2 0 0 2 0 0 0 0 2 0 1 0 0 0 
3 3 0 1 0 2 0 0 0 1 0 0 0 1 0 0 0 
Total 5 3 4 0 4 2 0 0 2 1 2 0 2 1 0 0 
 
Hgb 
1 2 1 1 0 1 1 0 0 1 0 0 1 1 0 0 0 
2 2 2 0 0 2 0 0 0 2 0 0 0 1 0 0 0 
3 1 2 1 0 1 1 0 0 1 0 1 0 1 0 0 0 
Total 5 5 2 0 4 2 0 0 4 0 1 1 3 0 0 0 
 
Hct 
1 1 0 3 0 0 2 0 0 1 0 1 0 1 0 0 0 
2 2 1 1 0 0 1 1 0 1 1 0 0 0 1 0 0 
3 1 1 2 0 1 0 1 0 0 0 1 1 1 0 0 0 
Total 4 2 6 0 1 3 2 0 2 1 2 1 2 1 0 0 
 
MCV 
1 0 0 1 0 0 1 1 0 1 0 1 0 0 0 1 0 
2 2 0 0 2 1 0 1 0 0 1 1 0 0 1 0 0 
3 1 1 1 0 1 1 0 0 0 0 1 0 1 0 0 0 
Total 3 1 2 2 2 2 2 0 1 1 3 0 1 1 1 0 
 
MCH 
1 2 0 2 0 1 1 0 0 1 0 0 1 1 0 0 0 
2 1 0 1 1 1 0 1 0 0 1 1 0 0 1 0 0 
3 2 2 0 0 2 0 0 0 0 0 1 0 1 0 0 0 
Total 5 2 3 1 4 1 1 0 1 1 2 1 2 1 0 0 
 
MCHC 
1 0 1 1 0 0 0 2 0 2 0 0 0 0 1 0 0 
2 2 0 2 0 0 0 2 0 0 2 0 0 0 0 1 0 
3 3 0 0 0 1 1 0 0 1 0 0 0 1 0 0 0 
Total 5 1 3 0 1 1 4 0 3 2 0 0 1 1 1 0 
 
Plts 
1 1 2 1 0 1 1 0 0 0 1 1 0 0 0 0 1 
2 1 1 2 0 1 1 0 0 0 0 1 1 0 0 1 0 
3 3 1 0 0 0 2 0 0 0 0 1 0 1 0 0 0 
Total 5 4 3 0 2 4 0 0 0 1 3 1 1 0 1 1 
 
RDW 
1 0 0 3 0 1 1 0 0 2 0 0 0 0 1 0 0 
2 2 1 1 0 2 0 0 0 1 0 0 0 1 0 0 0 
3 1 2 0 0 2 0 0 0 0 1 0 0 0 0 1 0 
Total 3 3 4 0 5 1 0 0 3 1 0 0 1 1 1 0 
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Chapter Four: Discussion  
 
 
4.1 Discussion. 
 
The CBC plays an important role in the diagnosis of a wide range of diseases as well as 
prognosis of the health status in genral. In order to fulfil this role, the results of CBC need to 
be as accurate as possible and show minimal interlaboratory variation. Therefore a need for 
laboratories to become more responsive to the needs of physicians making request by 
providing help in the presentation and interpretation (Kotila, 2006).  
 
In this study the interlaboratory and accuracy of hematology cell counters in patricipating 
laboratories were evaluated using fresh whole blood samples. Three samples from three 
healthy volunteers were collected and distributed directly after collection to sixty laboratories 
participating in this study. All participants were asked to run these samples in the same way 
they run their own patients’ samples.  
 
The CBC results were analyzed using the MS excel program to calculate the mean, SD, DI 
and the CV %. The implementation of a quality assessment program at the medical laboratory 
is an essential criteria toward implementing the good laboratory practice required by the 
regulatory authorities. The quality assessment program should include two parts, the IQC and 
the EQAS. The IQC program ensures that the laboratory delivers a reliable and reproducible 
results, while the EQAS controls the interlaboratory harmony.  
 
QC in automated hematology and related topics are extensively researched but there is still 
less knowledge on automation in other areas of Haematology (Kotila, 2006). Analysis of the 
data collected from sixty participant laboratories showed that only 11 (18.3 %) laboratories 
participate in an EQAS program while 49 (81.7 %) were not (Table 3.1.1). The EQAS 
programs were provided either by local programs like Al-Quds University or Health Work 
Committees (HWCs) or international programs like UK-NEQAS, RIQAS and CAP. 
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The reason that most laboratories do not participate in an EQAS is the high cost of the 
international programs. While the local programs lack sustainability and cover a small number 
of laboratories and usually the large laboratories or those that are affiliated with non-
governmental organizations or charitable societies. Additionally, the participation in an EQAS 
is not obligatory for the licence of a medical laboartory in Palestine. 
 
In West Bank there are a wide range of cell counters used; CellDyn is the most commonly 
used in Ramallah and Hebron, while Medonic is the most commonly used one in Nablus 
(Table 3.1.2). This study also showed that CellDyn (38.3 %) and Medonic (21.7 %) account 
for about 60.0 % of the cell counters used in participating laboratories. The choice of the cell 
counter mostly depends on the cost of the machine and availability of a reliable agent for the 
machine as well as benchmarking with other peer laboratories. Although the different 
machines vary in terms of the technology used for analysis of blood samples, they should 
essentially deliver comparable results for the same sample. In order to achieve this, the 
machines must be properly, carefully and regularly calibrated.  
 
The implementation of IQC at the laboratory starts with the use of a blood calibrator designed 
for calibration of the specific cell counter as indicated by the manufacturer. The proper 
calibration of cell counters requires the use of normal whole blood calibrators to calibrate the 
machine and the low and high blood calibrators are used to check the linearity of the machine 
which cover the range of values that can be found in patients’ samples. 
 
The use of the three types of calibrator is essential because the kinetics of the analysis method 
and the performance of the machine is not the same over the normal, low and high range (S M 
Lewis, 2006) Therefore, it’s always essential to calibrate or train the machine to perform 
properly over the values expected in patients’ samples. Among our study sample, it was 
observed that the number of the medical laboratories that use only normal blood calibrator is 
higher than those who use three blood calibrators (low, normal and high blood calibrators).
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The reason for the use of only normal calibrator is probably due to the cost needed to obtain 
the three blood calibrators compared to the purchase of one calibrator. Four (6.7 %) of the 
sixty medical laboratories do not use any type of blood calibrators, instead they select a 
patient sample from another laboratory and repeat it several times to check the reproducibility 
or precision of the machine, but this does not control the accuracy of the results. On the other 
hand, 26.6 % of laboratories use low, normal and high blood calibrators while 66.7 % of the 
medical laboratories use only normal calibrator (Table 3.1.3). This practice can be attributed 
to the lack of basic knowledge about the operation of the cell counter and thus these 
laboratory technicians require special attention and further education to better understand their 
machines properly. 
 
Another reason for not using a calibrator is the cost of the calibrator, but this is not justified 
because the analysis of a selected sample several times is also expensive and may even 
exceeds the price of the calibrator. Additionally, the cost of a false or inaccurate result is more 
costly than the blood calibrator because it affects adversely the image of the laboratory and 
may provoke a legal action against the laboratory. The performance of laboratories using three 
calibrators (L, N and H) based on DI calculations was better than those who use only normal 
calibrator. On average for WBCs as an example 42.5 % of laboratories that use three 
calibrators achieved excellent results compared to 33.6 % of laboratories who use normal 
control only (Table 3.2.3A).  
 
The frequency of using of blood calibrator is an important factor in IQC. The cell counters 
have to be calibrated daily before running the patients’ samples and the calibration may be 
repeated more than once in the same day based on the number of samples as well as per the 
manufacturer instructions. About two-thirds of the medical laboratories (64.0 %) use the 
blood calibrator on daily basis especially in Ramallah (95.0 %), but the percentage was much 
lower in Nablus (58.0 %) and Hebron (39.0 %), data shown in Table 3.1.4A. The results also 
show that a significant number of laboratories in Hebron and Nablus use the calibrator once or 
twice per week. While 5 laboratories (9.0 %) use the calibrator occasionally (Table 3.1.4B).  
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The occasional use of the calibrator can be attributed to the lack of knowledge concerning 
machine calibration. Laboratories that use three calibrators 16 out of 60 laboratories (26.6 %), 
all of them use it on a daily basis. The latter finding also indicate that, the technicians of 
laboratories who realized the need to have three levels of the calibrator (low, normal and high) 
have also rightly realize the need for machine calibration on a daily basis. Additionally, most 
of these laboratories participated in EQAS programs.  
 
An attempt to decrease the expenses may also play a role in the infrequent or occasional use 
of the calibrator. Another factor that may explain the use of only normal calibrator or the 
infrequent or occasional use of the calibrator is the low sample load since all large laboratories 
or those with a high work load use three calibrators and they use it on a daily basis. While 
most laboratories that use the normal calibrator alone are intermediate in size and about 50 % 
of them use the calibrator on a daily basis. 
 
The laboratories that use one calibrator not on a daily basis or do not use a calibrator are 
usually small laboratories with a low work load. For medical laboratories to produce reliable 
and reproducible results there should be intra- and inter-laboratory harmony of results. So that 
patients, who may have to repeat the analysis at different times or at different laboratories, 
should receive a quality service that helps in the management of the disease status and do not 
complicate the diagnosis or leads to inappropriate management.  
 
The results of this study showed that there are large differences in the values of CBC 
parameters before exclusion of outlier laboratories. Trimming of the raw data to exclude 
outlier laboratories has decreased the differences between lowest and highest values, but the 
differences are still large. The decrease in the difference between lowest and highest values 
was random and it did not show any pattern over the three rounds (Tables 3.2A & B).This 
study shows a large variation in the CBC results and a poor harmony in the results over the 
three rounds of the study. The high variability in the CBC results is due to several reasons. 
First some laboratories (6.7 %) do not calibrate their cell counters and one-third of medical 
laboratories (36.0 %) do not calibrate their cell counters on a daily basis (twice or once per 
week and occasionally).  
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The last point reveals that the quality control is not part of the medical laboratory philosophy 
as well as a lack of or negligence and/or ignorance of the basic principles of the operation of 
the cell counters. It also reveals the need for a national legislation that links the license of the 
medical laboratory to the implementation of IQC and participation in an EQAS. Secondly, 
some medical laboratories do not calibrate their cell counters appropriately, where they 
perform calibration depending on the range reported in the machine leaflet instead of the 
calibrator chart allowable percent, i.e., they fail to follow the instructions for calibration as 
provided by the cell counter manufacturer and calibrator supplier.  
 
The main objective of laboratory testing is to provide medically or clinically significant 
results that leads to the appropriate diagnosis of the disease status and improves the 
management of the patient. It is essential that the laboratory results such as the CBC should be 
as accurate as possible. The term clinically significant result means that each CBC parameter 
has an allowable range that allows the test value to deviate slightly from the true value 
without affecting the clinical decision or judgment of the patient’s health status. In this study, 
applying the criteria of the term “clinical significance of results” on the CBC results obtained 
from the participating laboratories, it was shown that 11-34 % of laboratories provided results 
that lie outside the allowable range (Table 3.2.1C).  
 
The performance of the medical laboratories in RBCs, Hgb, Hct and Plts was the poorest 
compared to other parameters (Table 3.2.1C). For example, evaluation of WBCs data showed 
that 11-14 % of laboratories lie outside the range because it has a wide reference range (4-11 
X10
9
/L). While evaluation of Hgb showed that 26-34 % of laboratories lie outside the range. 
Also Hgb should be one of the most precisely measured values because of the availability of 
an accurate and simple measurement method. Testing the harmony of the laboratory results at 
one time point may be biased, therefore three samples were sent to the participant laboratories, 
each separated from other samples by about three weeks. Analysis of the data over the three 
rounds was supposed to give a better overview of the performance of the laboratories.
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The performance of the participant laboratories was also analyzed based on the DI, which is 
also used by the UK-NEQAS and WHO. The results of this study indicate that the overall 
performance of the medical laboratories was poor in general and the same in all three rounds.  
To further analyze the performance of laboratories statistically, the CV % of each CBC 
parameter was analyzed by Chi square for goodness-of-fit.  
 
Based on the CV %, there was no statistically significant change in the performance of the 
laboratories over the three rounds of the study and the slight changes seen over the three 
rounds in the values of the CBC are due to random changes. Although, for WBCs as an 
example 33.3 %, 33.8 % and 31.6 % of laboratories have achieved excellent results in round 
one, two and three, respectively, based on DI calculation (Table 3.2.1B1). Additionally, 
analysis of the performance of laboratories based on the type of cell counter also showed the 
performance is not affected by the type of cell counter (Table 3.2.4). 
 
4.2 Recommendations. 
 
The evaluation of quality control in the hematology laboratories in West Bank is an essential 
process. The large variations of the results of the CBC tests that have been shown in this study 
confirms the need of a national EQAS program for the medical laboratories in Palestine as 
well as the need for a legislation to link the license of medical laboratories to the 
implementation of IQC and participation in an EQAS.  
 
The development of a local EQAS should encourage more laboratories to participate due to 
lower costs and a more accessible technical support and consultation. The harmony of the 
CBC results is poor, which confirms the problem of lacking a national quality control 
program. So, the need of the implementation of an EQAS in Palestine is essential for ensuring 
harmonization of results between medical laboratories. This harmonization enables all 
medical laboratories to achieve results which are in agreement with each other to reach a 
common level of standardization. In hematology, CBC is still the key for the diagnosis of a lot 
of diseases and thus warrants more attention.  
 54 
 
Further studies to evaluate the consensus and accuracy of hematology laboratories in Palestine 
are needed to evaluate the performance of participants over a relatively longer period of time 
to allow for feedback from participants based on each result and examine their improvement 
over two or three rounds.  
 
Local universities and institutes or any other nongovernmental organizations can participate 
with teams experience to improve the status of the Palestinian medical laboratories and 
introduce better laboratory services to the Palestinian patient. Alternatively, laboratories 
should all be asked by a national regulatory authority to implement IQC and participate in an 
EQAS and then evaluate their performance and guide them to improve their performance. 
Additionally, all laboratory technicians should be asked to participate in continuing education 
programs specifically targeted to tackle practical aspects of laboratory work.  
 
The history of the last 20 years of EQA programs in clinical cell analysis has shown that every 
project has germinated first in a soil made of clinical need and scientific enthusiasm, and then 
it was transplanted in a solid institutional background, where it could mature, get stronger, and 
disseminate its educational fruits (Brando et al., 2007).  
 
The success of the scheme implementation will provide opportunity to widen the scope of the 
participant medical laboratories. Since further studies for longer periods are needed the small 
local studies still provide the necessary stimulus to the continuous improvement of the 
scientifically aspects of EQAS schemes (Brando et al., 2007). Finally, the success of applying 
EQAS programs gives for sure an increased confidence in the laboratory results.  
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Appendices: 
 
Appendix A  
 
Results of the CBC tests for tubes number 1, 20, 40, and 60 on a CellDyn 1700 machine 
 
CBC 
Parameter 
 
WBCs 
 
RBCs 
 
Hgb 
 
Hct 
 
MCV 
 
MCH 
 
MCHC 
 
PLTs 
 
RDW 
Tube No. 
1 6.6 5.33 15.3 47.3 88.8 28.7 32.3 176 13.4 
20 6.7 5.20 15.1 47.0 88.5 28.5 32.1 173 13.2 
40 6.6 5.31 15.2 47.1 88.6 28.6 32.2 179 13.3 
60 6.5 5.29 15.3 47.2 88.8 28.8 32.2 177 13.4 
 
 
Appendix B The recorded time and temperature of the refrigerators during the study 
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Appendix B2 in Ramallah round two 
  
 
Appendix B3 in Ramallah round three 
 
 
0
1
2
3
4
5
6
0
9
:2
3
0
9
:3
0
0
9
:4
0
0
9
:5
0
0
9
:5
8
1
0
:0
1
1
0
:0
7
1
0
:1
0
1
0
:1
6
1
0
:2
2
1
0
:2
8
1
0
:3
1
1
0
:3
6
1
0
:4
3
1
0
:5
1
1
0
:5
5
1
0
:5
7
1
1
:0
4
1
1
:2
8
1
1
:3
3
Te
m
p
er
at
u
re
 /
 D
e
gr
ee
 C
el
si
u
s
Time
Temperature
0
1
2
3
4
5
6
7
8
9
10
0
9
:3
0
0
9
:4
7
0
9
:5
3
1
0
:0
0
1
0
:1
1
1
0
:1
4
1
0
:1
9
1
0
:2
4
1
0
:5
0
1
1
:0
1
1
1
:0
4
1
1
:0
6
1
1
:0
8
1
1
:1
5
1
1
:2
1
1
1
:2
4
1
1
:2
9
1
1
:3
2
1
2
:0
5
1
2
:1
5
Te
m
p
er
at
u
re
 /
 D
e
gr
e
e
 C
e
ls
iu
s
Time
Temperature
 61 
 
 
 
 
Appendix B4 in Nablus round one 
 
 
 
Appendix B5 in Nablus round two 
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Appendix B6 in Nablus round three 
 
 
 
Appendix B7 in Hebron round one 
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Appendix B8 in Hebron round two 
 
 
 
Appendix B9 in Hebron round three 
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Appendix C The lowest and highest values of the hematological parameters recorded in the three 
rounds in ascending order. 
Round One 
WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
3.7 4.4 11.5 34.1 72.2 23.9 30.4 173 10.3 
4.9 5.7 14.9 44.2 75.2 24.3 30.5 208 11.0 
4.9 5.7 15.4 44.8 75.9 24.6 31.3 222 11.5 
4.9 5.9 15.6 45.8 75.9 24.7 31.4 232 11.7 
4.9 5.9 15.6 46.0 76.0 25.0 31.4 232 12.2 
5.0 5.9 15.6 46.4 76.1 25.2 31.5 233 12.2 
5.0 6.0 15.7 46.9 76.5 25.2 31.5 237 12.2 
5.0 6.1 15.8 47.3 77.0 25.2 31.5 238 12.3 
5.0 6.1 15.8 47.9 77.0 25.4 31.6 238 12.3 
5.1 6.1 15.9 48.0 77.0 25.4 31.7 240 12.4 
5.1 6.1 15.9 48.2 77.0 25.4 31.7 242 12.6 
5.2 6.1 15.9 48.2 77.2 25.6 31.9 243 12.6 
5.2 6.1 16.0 48.3 77.3 25.6 32.0 244 12.6 
5.2 6.1 16.0 48.3 77.3 25.6 32.0 244 12.7 
5.2 6.1 16.0 48.3 77.4 25.6 32.1 245 12.7 
5.2 6.1 16.0 48.4 77.6 25.7 32.1 248 12.7 
5.2 6.1 16.0 48.4 77.8 25.7 32.1 248 12.7 
5.2 6.2 16.1 48.4 77.9 25.7 32.1 249 12.7 
5.3 6.2 16.2 48.7 77.9 25.8 32.1 251 12.8 
5.3 6.2 16.2 48.8 78.0 25.8 32.1 251 12.9 
5.3 6.2 16.2 48.9 78.0 25.9 32.3 253 12.9 
5.4 6.2 16.2 49.0 78.1 25.9 32.3 255 13.0 
5.4 6.2 16.3 49.0 78.1 25.9 32.4 257 13.0 
5.5 6.2 16.3 49.4 78.4 26.0 32.4 257 13.1 
5.5 6.2 16.3 49.6 78.5 26.0 32.4 258 13.1 
5.5 6.3 16.3 49.6 78.6 26.0 32.4 258 13.1 
5.5 6.3 16.4 49.9 78.9 26.1 32.4 259 13.1 
5.5 6.3 16.4 49.9 78.9 26.1 32.5 259 13.1 
5.5 6.3 16.4 50.0 79.1 26.1 32.6 262 13.1 
5.6 6.3 16.4 50.0 79.3 26.2 32.6 262 13.2 
5.6 6.3 16.4 50.1 79.4 26.2 32.7 262 13.3 
5.6 6.3 16.4 50.2 79.9 26.2 32.9 263 13.4 
5.6 6.3 16.4 50.5 79.9 26.2 32.9 266 13.6 
5.6 6.3 16.4 50.6 80.0 26.2 33.0 267 13.6 
5.6 6.3 16.5 50.6 80.2 26.2 33.0 268 13.7 
5.6 6.3 16.6 50.7 80.4 26.2 33.0 270 13.8 
5.7 6.4 16.6 50.7 80.4 26.4 33.0 271 13.8 
5.7 6.4 16.6 50.7 80.5 26.4 33.2 275 13.8 
5.7 6.4 16.7 50.8 80.7 26.5 33.2 278 13.8 
5.7 6.4 16.7 50.9 80.7 26.6 33.3 279 13.9 
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WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
5.7 6.4 16.7 51.1 80.8 26.6 33.4 286 13.9 
5.8 6.4 16.7 51.1 80.8 26.7 33.6 290 13.9 
5.8 6.4 16.8 51.1 80.9 26.8 33.7 290 14.0 
5.8 6.4 16.8 51.2 81.1 26.8 33.7 292 14.0 
5.8 6.4 16.8 51.2 81.1 26.8 33.7 298 14.1 
5.9 6.4 16.8 51.3 81.3 26.9 33.9 299 14.1 
5.9 6.4 16.8 51.4 81.3 27.1 33.9 303 14.1 
5.9 6.5 16.9 51.4 81.4 27.2 34.0 303 14.2 
5.9 6.5 16.9 51.5 81.8 27.2 34.1 303 14.2 
5.9 6.5 16.9 52.0 82.2 27.3 34.1 305 14.2 
5.9 6.5 17.0 52.1 82.7 27.4 34.2 306 14.4 
6.0 6.5 17.1 52.5 82.7 27.4 34.4 310 14.5 
6.0 6.5 17.1 52.8 82.7 27.5 34.5 311 15.0 
6.0 6.5 17.2 52.9 83 27.5 34.6 314 15.0 
6.1 6.5 17.2 53.1 83.7 27.5 34.7 315 15.0 
6.1 6.5 17.4 53.9 84.0 27.5 34.7 317 15.1 
6.2 6.6 17.5 54.0 84.1 27.5 34.8 319 15.1 
6.3 6.7 17.5 54.2 86.4 27.6 35.3 322 15.9 
6.5 6.7 17.6 54.8 87.1 27.7 35.3 327 16.5 
6.7 6.8 17.9 55.8 87.3 34.8 35.4 349 16.9 
 
Round Two 
WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
5.1 4.3 12.9 35.4 79.8 26.2 18.1 120 9.4 
5.2 4.9 13.4 41.3 79.8 26.5 30.9 133 10.2 
5.3 4.9 13.5 41.4 80.1 26.7 31.2 133 11.2 
5.3 4.9 14.0 41.6 81.1 27.0 31.6 165 11.3 
5.3 4.9 14.1 41.6 81.2 27.1 31.7 176 11.7 
5.3 4.9 14.1 41.9 81.4 27.3 32.2 176 11.8 
5.4 4.9 14.3 41.9 81.6 27.4 32.3 176 11.8 
5.5 5.0 14.3 41.9 81.7 27.4 32.4 181 11.9 
5.5 5.0 14.3 42.0 81.8 27.5 32.6 184 11.9 
5.5 5.0 14.3 42.4 82.1 27.5 32.6 186 12.0 
5.5 5.1 14.4 42.4 82.2 27.5 32.6 188 12.1 
5.6 5.1 14.4 42.4 82.2 27.6 32.6 190 12.3 
5.6 5.1 14.5 42.5 82.3 27.6 32.9 191 12.4 
5.6 5.1 14.5 42.5 82.3 27.6 33.0 192 12.6 
5.6 5.1 14.5 42.6 82.5 27.8 33.0 195 12.7 
5.7 5.1 14.5 42.9 82.6 27.8 33.0 195 12.7 
5.7 5.1 14.6 43.0 82.9 27.9 33.1 195 12.7 
5.7 5.1 14.6 43.0 82.9 27.9 33.1 198 12.7 
5.7 5.1 14.7 43.1 83.0 28.0 33.2 202 12.7 
5.7 5.1 14.7 43.1 83.4 28.0 33.2 203 12.7 
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WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
5.8 5.1 14.7 43.2 83.6 28.1 33.3 203 12.8 
5.8 5.1 14.7 43.2 83.6 28.3 33.3 204 12.8 
5.8 5.2 14.7 43.3 83.7 28.3 33.3 204 12.8 
5.8 5.2 14.8 43.3 83.7 28.4 33.3 205 12.9 
5.8 5.2 14.8 43.4 83.9 28.4 33.4 207 12.9 
5.8 5.2 14.8 43.7 84.0 28.4 33.4 207 12.9 
5.8 5.2 14.8 43.8 84.0 28.4 33.4 209 13.0 
5.8 5.2 14.8 43.8 84.2 28.5 33.4 210 13.0 
5.9 5.2 14.8 43.8 84.4 28.6 33.5 210 13.0 
5.9 5.2 14.9 44.0 84.4 28.6 33.6 212 13.1 
5.9 5.2 14.9 44.0 84.5 28.6 33.6 214 13.1 
5.9 5.2 14.9 44.1 84.5 28.7 33.7 216 13.2 
5.9 5.2 14.9 44.3 84.9 28.7 33.7 216 13.2 
5.9 5.2 14.9 44.3 85.1 28.7 33.7 218 13.2 
5.9 5.2 14.9 44.4 85.1 28.7 33.8 219 13.3 
6.0 5.2 14.9 44.4 85.2 28.8 33.9 219 13.3 
6.0 5.2 14.9 44.5 85.2 28.8 34.0 220 13.4 
6.0 5.3 14.9 44.6 85.5 28.8 34.0 220 13.5 
6.0 5.3 14.9 44.8 85.5 28.9 34.1 222 13.6 
6.0 5.3 15.0 44.8 85.5 28.9 34.3 222 13.7 
6.0 5.3 15.0 44.9 85.9 28.9 34.3 223 13.7 
6.1 5.3 15.0 44.9 85.9 29.0 34.4 223 13.7 
6.1 5.3 15.1 45.0 86.1 29.0 34.5 223 13.8 
6.1 5.3 15.1 45.1 86.2 29.0 34.5 228 13.8 
6.1 5.3 15.1 45.1 86.2 29.0 34.5 228 13.9 
6.1 5.3 15.1 45.1 86.3 29.1 34.6 229 13.9 
6.2 5.3 15.1 45.2 86.4 29.1 34.6 230 13.9 
6.2 5.3 15.1 45.3 86.5 29.3 34.9 236 14.0 
6.2 5.4 15.2 45.3 86.6 29.4 34.9 242 14.1 
6.2 5.4 15.2 45.4 86.8 29.4 34.9 242 14.1 
6.2 5.4 15.3 45.4 86.9 29.5 35.0 244 14.1 
6.2 5.4 15.3 45.6 87.0 29.5 35.0 244 14.2 
6.3 5.4 15.3 45.9 87.9 29.5 35.3 246 14.4 
6.4 5.5 15.4 46.8 88.4 29.6 35.3 255 14.5 
6.4 5.5 15.5 47.4 88.8 30.1 35.4 258 14.6 
6.6 5.6 15.7 48.7 89.8 30.2 35.5 264 14.7 
6.6 5.6 16.0 58.0 90.6 30.3 36.0 274 14.8 
7.0 6.7 19.4 59.6 91.2 30.5 36.3 276 15.4 
7.1 6.9 19.4 82.1 159.4 30.8 36.6 298 16.0 
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Round Three 
WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
5.7 3.9 12.5 33.6 80.0 25.2 30.0 168 10.0 
5.9 4.5 13.1 40.9 82.8 27.1 30.4 184 10.6 
6.1 4.9 14.5 44.0 85.1 27.7 30.6 190 10.9 
6.2 4.9 14.7 44.1 85.3 28.3 31.7 202 11.5 
6.3 5.1 14.9 44.8 85.6 28.3 31.8 203 11.7 
6.3 5.8 15.3 45.5 85.7 28.6 32.0 204 11.9 
6.4 5.8 15.4 45.6 85.7 28.7 32.1 208 12.1 
6.4 5.1 15.4 45.7 85.7 28.7 32.1 208 12.1 
6.5 5.1 15.5 45.8 86.0 28.8 32.1 209 12.1 
6.6 5.1 15.6 45.9 86.5 28.8 32.2 214 12.1 
6.6 5.2 15.6 46.0 86.7 28.8 32.3 217 12.2 
6.6 5.2 15.6 46.0 86.7 29.0 32.3 217 12.3 
6.6 5.2 15.6 46.0 86.8 29.1 32.4 217 12.3 
6.6 5.3 15.6 46.2 87.1 29.1 32.5 218 12.3 
6.6 5.3 15.7 46.5 87.3 29.2 32.6 219 12.3 
6.7 5.3 15.8 46.6 87.4 29.2 32.7 220 12.5 
6.7 5.3 15.8 46.8 87.5 29.3 32.7 222 12.6 
6.7 5.3 15.8 46.9 87.5 29.3 32.8 223 12.6 
6.7 5.3 15.8 47.1 87.7 29.3 32.9 228 12.6 
6.8 5.3 15.8 47.2 87.7 29.3 33.0 229 12.7 
6.8 5.3 15.8 47.2 88.2 29.3 33.0 229 12.8 
6.8 5.3 15.9 47.4 88.2 29.4 33.1 229 12.8 
6.9 5.3 15.9 47.4 88.4 29.4 33.1 230 13.0 
6.9 5.4 15.9 47.4 88.4 29.4 33.2 231 13.0 
6.9 5.4 15.9 47.4 88.5 29.4 33.2 233 13.1 
6.9 5.4 16.0 47.5 88.5 29.5 33.3 235 13.2 
6.9 5.4 16.0 48.0 88.7 29.6 33.4 235 13.3 
7.0 5.4 16.0 48.0 88.8 29.7 33.5 236 13.3 
7.0 5.4 16.1 48.0 88.8 29.7 33.5 236 13.3 
7.0 5.4 16.1 48.0 88.9 29.7 33.5 236 13.4 
7.0 5.4 16.1 48.1 88.9 29.7 33.5 237 13.4 
7.0 5.4 16.1 48.1 89.0 29.8 33.5 239 13.4 
7.0 5.4 16.1 48.2 89.1 29.9 33.6 239 13.4 
7.0 5.4 16.1 48.3 89.1 29.9 33.6 241 13.5 
7.0 5.4 16.1 48.3 89.6 30.0 33.7 244 13.5 
7.0 5.5 16.2 48.5 89.8 30.1 33.7 248 13.6 
7.0 5.5 16.2 48.6 90.0 30.1 33.7 248 13.6 
7.1 5.5 16.2 49.0 90.1 30.1 33.8 249 13.7 
7.1 5.5 16.3 49.1 90.1 30.1 33.9 251 13.7 
7.1 5.5 16.3 49.3 90.1 30.2 34.0 251 13.7 
7.1 5.5 16.3 49.4 90.2 30.2 34.0 252 13.7 
7.1 5.5 16.3 49.4 90.2 30.3 34.0 258 13.8 
7.2 5.5 16.3 49.5 90.5 30.4 34.1 260 13.8 
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WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
7.2 5.5 16.3 49.6 90.9 30.5 34.2 261 13.9 
7.2 5.5 16.3 49.6 91.0 30.5 34.4 262 13.9 
7.3 5.5 16.4 49.8 91.0 30.6 34.4 264 14.0 
7.3 5.6 16.4 49.8 91.1 30.7 34.4 266 14.1 
7.3 5.6 16.4 49.8 91.2 30.7 34.6 268 14.2 
7.4 5.6 16.5 50.0 91.5 30.8 34.6 268 14.3 
7.5 5.6 16.6 50.1 91.7 31.0 34.6 273 14.4 
7.5 5.6 16.6 50.6 92.0 31.1 34.7 276 14.5 
7.5 5.6 16.7 50.6 92.0 31.1 35.0 276 14.5 
7.9 5.6 16.8 50.7 92.1 31.3 35.4 280 14.5 
7.9 5.7 16.8 51.3 92.1 31.7 35.6 281 14.6 
7.9 5.8 16.9 51.5 93.0 32.0 35.7 287 15.6 
8.0 6.3 17.3 53.0 94.2 32.2 36.5 291 15.6 
8.5 6.4 19.0 56.6 95.8 32.3 37.2 297 17.6 
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Appendix D: The Questionnaire 
 
: ىاوٌعب تيثحب تسارد 
 
Evaluation of Quality Control in the Hematology Laboratories in the West Bank, 
Palestine: A Consensus Study. 
 
 لهبشلا مذلا صحف جئبخً قفاوح ىذه تفزعول تسارذلا ٍذه جووص( (CBC  يف تيبطلا ثازبخخولا فلخخه ييب
تيبزغلا تفضلاىإ ،  ىا نلعلا عه ، تسارذلا ٍذه يف تكربشولا ربيخ كل يقبيو تيزس يقبخس ثبهولعولا تفبك
كخكربشه ٍبًدأ تلئسلأا يع كخببجاو لا يلع عفٌلبب دوعخسثحبب ثازبخخولا تفبك يلعو تيبطلا سلف يفييط. 
 
 يبطلازبخخولا نقر ..................... :          خيربخلا    .................... : تعبسلا................. :  
 يبطلا زبخخولا نسا............................................................................................... :  
 يبطلا زبخخولا زيذه نسا :.........................................................................................  
 يبطلا زبخخولا ىاوٌع :............................................................................................  
يبطلا زبخخولا فحبه :...............................................................................................  
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
1. Type and version of your cell counter: ………………………………………………. 
 
2. Do you buy blood control for calibration?                             [Yes]       [No] 
 
3. If No, How do you calibrate your machine? …………………………………………                       
 
4. Do you use only normal control?                                            [Yes]       [No] 
 
5. Do you use normal, low or high controls?                             [Yes]       [No] 
 
6. What is the brand of blood control you use? ………………………………………... 
 
7. Do you share the blood control with others?                         [Yes]       [No] 
 
8. Are you participating in EQAS system?                                [Yes]       [No] 
 
9. If Yes, What is the name of the program? …………………………………………... 
 
10. How often you run the blood control on your machine? 
           [     ] Daily      [     ] Once a Week            [     ] Twice a Week            [     ] Occasional  
      What is the daily average load of the CBC? …………………………………………….. 
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Appendix E The performance of the CBC results of all medical laboratories in the three rounds 
Appendix E1The performance of the CBC results of all medical laboratories in round one 
Key: E: Excellent, G: Good, S: Satisfactory, and SE: Serious Error. 
Lab # WBCs RBCs Hgb Hct MCV MCH MCHC PLTs RDW 
1 Excluded Excluded Excluded Excluded (S) (E) (G) Excluded (G) 
2 (S) (E) (G) (G) (G) (G) (E) (G) (E) 
3 (S) (E) (G) (E) (G) (G) (S) (G) (E) 
4 (S) (S) (E) (G) (G) (S) (S) (G) (G) 
5 (S) (E) (S) (E) (E) (S) (S) (E) (E) 
6 (G) (S) (G) (E) (S) (E) (G) (E) (E) 
7 (G) (E) (E) (G) (S) (E) (S) (S) (G) 
8 (G) (G) (G) (E) (E) (E) (E) (E) (E) 
9 (G) (S) (S) (S) (E) (E) (E) (G) (G) 
10 (E) (SE) (S) (S) (E) (G) (S) (S) (G) 
11 (E) (G) (G) (E) (S) (E) (S) (E) (S) 
12 (E) (E) (S) (E) (E) (S) (S) (S) (G) 
13 (E) (G) (G) (G) (G) (E) (E) (S) (E) 
14 (E) (E) (E) (E) (G) (E) (G) (S) (E) 
15 (E) (G) (E) (E) (SE) (S) (E) (S) (E) 
16 (G) (S) (E) (G) (E) (G) (E) (S) (S) 
17 (S) (E) (E) (G) (G) (E) (E) (E) (S) 
18 (S) (E) (G) (G) (G) (G) (S) (G) (G) 
19 Excluded (S) (S) (E) (E) (G) (S) (E) (S) 
20 (E) (G) (E) (E) (S) (E) (G) (SE) (G) 
21 (G) (S) (S) (S) (G) (E) (S) (G) (S) 
22 (E) (E) (S) (E) (E) (S) (S) (S) (G) 
23 (E) (G) (S) (S) (G) (G) (E) (S) (S) 
24 (S) (G) (G) (S) Excluded (S) (S) (G) Excluded 
25 (E) (S) (S) (E) (S) (SE) (S) (S) (E) 
26 (S) (S) (E) (S) (G) (S) Excluded (S) (G) 
27 (S) (G) (G) (G) (E) (S) (S) (E) (G) 
28 (G) (E) (G) (G) (G) (G) (G) (E) (E) 
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29 (E) (E) (E) (G) (S) (E) (S) (E) (E) 
30 (S) (E) (E) (G) (S) (E) (G) (S) Excluded 
31 (G) (E) (E) (E) (E) (E) (G) (E) (E) 
32 (S) (G) (G) (E) (G) (E) (G) (E) (E) 
33 (G) (G) (G) (E) (S) (S) (E) (E) (S) 
34 (E) (E) (E) (E) (E) (E) (E) (G) Excluded 
35 (S) (SE) (S) (SE) (G) (S) Excluded (E) (G) 
36 (S) (E) (E) (S) Excluded (E) Excluded (G) Excluded 
37 (E) (E) (E) (E) (G) (G) (G) (S) (G) 
38 (E) (E) (E) (E) (G) (G) (G) (P) (G) 
39 (S) (G) (E) (S) (S) (G) (S) (E) (G) 
40 (S) (G) (E) (G) (E) (G) (S) (G) (S) 
41 (SE) (E) (E) (E) (G) (E) (E) (E) (E) 
42 (S) (E) (G) (G) (S) (G) (S) (G) (S) 
43 (E) (G) (S) (G) (E) (G) (S) (S) (S) 
44 (E) (S) (S) (S) (G) (E) (E) (E) (G) 
45 (G) (E) (G) (E) (G) (S) (G) (S) Excluded 
46 (S) (E) (S) (S) Excluded (S) (G) (G) (S) 
47 (G) (S) (G) (G) (G) (S) (G) (E) (G) 
48 (S) (E) (E) (G) (G) (E) (S) Excluded (E) 
49 (G) (G) (E) (E) (G) (S) (E) (E) (G) 
50 (G) (S) (E) (S) Excluded (S) (S) (S) (S) 
51 (S) (SE) (S) (SE) (G) (S) Excluded (S) (G) 
52 (S) (E) (E) (E) (E) (E) (E) (G) (E) 
53 (E) (S) (S) (S) (S) (E) (G) (S) (SE) 
54 (E) (E) (G) (E) (E) (S) (G) (E) (G) 
55 Excluded (S) (G) (SE) (SE) (G) (SE) (S) (S) 
56 (S) (G) (E) (E) (S) (S) (E) (G) (G) 
57 (G) (G) (SE) (S) (S) (SE) (E) (S) (E) 
58 (S) (S) (SE) (G) (S) Excluded (G) (G) (S) 
59 (E) (E) (G) (E) (S) (S) (E) (G) (E) 
60 (E) (E) (E) (E) (G) (E) (G) (G) (G) 
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Appendix E2 The performance of the CBC results of all medical laboratories in round two 
Key: E: Excellent, G: Good, S: Satisfactory, and SE: Serious Error. 
Lab # WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
1 (E) (E) (S)  (G)  (G)  (G) (E) (E) (S) 
2 (E) (E) (E) (E)  (G)  (G) (E) (S) (E) 
3 (E) (E) (E)  (G) (S)  (G) (S) (E) (E) 
4 (E) (S) (E)  (G)  (G) (S) (E)  (G)  (G) 
5 (S)  (G) (S) (E) (E) (E)  (G) (S)  (G) 
6  (G) (E) (E) (E)  (G) (E) (E) (S)  (G) 
7 (E) (E) (E)  (G)  (G)  (G) (E) (S)  (G) 
8  (G) (E) (E) (E)  (G)  (G) (E) (E) (E) 
9 The Cell Counter was not available 
10 (E)  (G) (S)  (G) (E) (E) (E) (E) (E) 
11 (S)  (G) (E) (S) (SE) (S) (S) (S) (S) 
12 (E) (E)  (G)  (G)  (G) (E) (E)  (G) (E) 
13 (S)  (G) (E)  (G) (E) (S)  (G)  (G) (S) 
14  (G)  (G) (S) (E) (E)  (G)  (G) (S) (E) 
15  (G) (S) (E) (E) (S) (S) (E) (E) (E) 
16 (E) (E) (E)  (G) (E) (E) (E) (E) (S) 
17 (E) (S) (E)  (G) (E)  (G)  (G) (E) (S) 
18 (S)  (G) (E)  (G) (E) (S) (S) (E) (E) 
19 Excluded  (G) (S) (E)  (G) (S) (S) (S) (S) 
20 (S) (E) (E)  (G)  (G)  (G) (S) (S) (E) 
21 Excluded (E)  (G) (E)  (G)  (G) (S) (S) (S) 
22 (S) (S) (SE) (S) (E) (S) (S)  (G) (S) 
23 (E)  (G) (SE) (E) (E) Excluded (SE) (E)  (G) 
24 (S) (SE) (E) (E) (S) Excluded (S)  (G) Excluded 
25 (S)  (G) (E) (E) (S) (S) (E) (S) (S) 
26 (SE) Excluded Excluded (SE)  (G) (S) (SE) Excluded  (G) 
27  (G) (E)  (G) (E) (E)  (G) (E)  (G) (E) 
28 (S) (E) (E)  (G) (E) (E) (E) (S)  (G) 
29 (S)  (G) (E) (S) (S) (E) (S)  (G) (E) 
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30  (G) (E) (E)  (G) (S) (E)  (G)  (G) Excluded 
31 (S) Excluded Excluded Excluded  (G)  (G)  (G) Excluded  (G) 
32  (G)  (G) (S) (E)  (G) (E)  (G) (E) (S) 
33  (G) (S) (E) (E) (S) (S) (E) (E)  (G) 
34  (G)  (G) (E) (E) (E) (E) (E) (S) Excluded 
35 (E) (S)  (G) (S) (E) Excluded (SE)  (G)  (G) 
36 (S)  (G)  (G) (E) (E) (E) (E)  (G) (E) 
37 (E) (E) (E)  (G) (S) (E)  (G) (S) (SE) 
38 (E) (E) (E) (E) (E)  (G)  (G) (E) (E) 
39 (E) (E)  (G)  (G)  (G) (E) (E) (E) (E) 
40 (E) (E) (S) (S) (S) (S)  (G) (E) (S) 
41 Excluded  (G)  (G)  (G) (E) (S) (S) Excluded (E) 
42 (S) (E) (E) Excluded Excluded (E) Excluded  (G) (E) 
43  (G) (E) (S)  (G)  (G) (SE) (SE) (S) (E) 
44 (E)  (G)  (G)  (G) (E) (E) (E) (E) (E) 
45 (S) (E)  (G) (S) (SE) (S) (S) (E) (S) 
46 Excluded (S)  (G) (E) (SE) Excluded (E) (S) (E) 
47 (E) (S) (S)  (G) (E) (E) (E) (E) (E) 
48  (G) (E) (S) (E)  (G) (S) (E) (SE)  (G) 
49  (G) (S) (E)  (G) (E) (S)  (G) (E) (E) 
50 (S) (S) (E)  (G) (E) (SE) (S) (E)  (G) 
51 (E) (E) (E)  (G)  (G) (E)  (G) (E) (E) 
52 (S) (S) (E)  (G)  (G) (S)  (G) (SE) Excluded 
53  (G) (S) (E) (S)  (G) (S) (S) (E) (S) 
54  (G)  (G) (S) (E) (S) (SE)  (G) (E) (S) 
55  (G) (SE) (SE) (SE)  (G) (E)  (G)  (G) (SE) 
56 (S) Excluded Excluded Excluded  (G) (E) (E) Excluded (E) 
57 Excluded (S) (E) (E) (S)  (G)  (G) (S) (E) 
58 (E)  (G) (S) (E) (S) (E) (S)  (G) (S) 
59 (E) (E) (S) (E) (E) (S)  (G) (E) (E) 
60 (S) (E) (E)  (G)  (G) (E)  (G) (E) (S) 
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Appendix E3 The performance of the CBC results of all medical laboratories in round three 
Key: E: Excellent, G: Good, S: Satisfactory, and SE: Serious Error. 
Lab # WBCs RBCs Hgb Hct MCV MCH MCHC PLTs  RDW 
1 (SE) Excluded Excluded Excluded (S) (SE) Excluded Excluded  (G) 
2 (E) (E)  (G) (S) (S)  (G) (E) (S)  (G) 
3 (E) (E)  (G) (E)  (G) (E)  (G) (E)  (G) 
4 (E) (SE) (E) (S) (S) Excluded (S) (S)  (G) 
5 (E) (S) (SE) (S) (E)  (G) (S)  (G) (E) 
6  (G) (E) (E) (E) (E)  (G)  (G) (S)  (G) 
7  (G) (S)  (G) (S) (S)  (G) (S) (S) (E) 
8  (G) (E) (E) (S)  (G) (E)  (G)  (G) (E) 
9 (E) (E)  (G) (E)  (G) (E)  (G) (E) (E) 
10 (E) (S) (E)  (G) (E) (S) (S) (S)  (G) 
11 Excluded (E) (E) (E) (E) (E) (E) (E)  (G) 
12  (G) Excluded Excluded Excluded (E) (E) (E) (S) (E) 
13 (E)  (G) (E) (S) (S)  (G) (S) (E) (E) 
14 Excluded Excluded Excluded Excluded (E) (S) (S) (S)  (G) 
15  (G)  (G)  (G)  (G) Excluded (S) (E) (S) (E) 
16 (E)  (G)  (G)  (G)  (G) (E) (E) (E) (S) 
17 (E) (S) (E) (S) (E) (S) (S) (E) (S) 
18 (S) (E) (E) (E) (E) (E)  (G)  (G) (E) 
19 Excluded  (G) (S) (E) (S) (S) (SE) (E) (S) 
20 Excluded (E) (E) (E) (E) (E) (E) (E) (S) 
21 (S) (E) (E)  (G) (S)  (G) (S) (S)  (G) 
22 (S) (SE) (SE) (SE) (E)  (G) (E) (E) (S) 
23 (S) (E) (SE) (E) (E) Excluded Excluded (S) (S) 
24 (S) (SE) (E)  (G) (S) (SE) (S) (E) Excluded 
25  (G)  (G) (E) (E) (S) (S) (E)  (G)  (G) 
26 (S) (S) (E) (SE) (S) (SE) Excluded (S)  (G) 
27  (G) (E)  (G) (E) (E)  (G) (S) (E)  (G) 
28 (S) (E) (E)  (G)  (G) (E)  (G)  (G)  (G) 
29 (SE) (E)  (G) (S)  (G) (E) (E)  (G) (E) 
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30  (G) (E) (E) (S) (S) (E) (S)  (G) Excluded 
31  (G)  (G) (E) (S) (S) (S) (E) (E) (S) 
32 The Cell Counter was not available 
33  (G) (S) (E) (E) (S) (S) (E)  (G) (E) 
34  (G) (S)  (G)  (G) (E)  (G)  (G)  (G) Excluded 
35 The Cell Counter was not available 
36 (E) (E)  (G) (S) Excluded  (G) Excluded (E) Excluded 
37 (E) (S) (S) (E)  (G) (E)  (G)  (G) (S) 
38  (G)  (G) (E) (E)  (G) (S)  (G) (S)  (G) 
39 The Cell Counter was not available 
40 (E) (E) (E) (E) (E) (E) (E)  (G)  (G) 
41 (S) (E) (E)  (G)  (G)  (G) (S) (E)  (G) 
42  (G)  (G) (E) (S) (S)  (G) (E)  (G)  (G) 
43 (S) (S) (SE) (S)  (G) (E) (S) (E) (S) 
44 (E)  (G) (E)  (G)  (G) (E)  (G) (E) (S) 
45  (G) (E)  (G)  (G) (S)  (G) (E) (E) (S) 
46  (G) (S) (S) (S)  (G) (E) (E)  (G) (E) 
47 (E) (E) (S) (E) (E) (S) (S) (S) (E) 
48 (S) (E)  (G) (S)  (G) (E) (E) (SE) (E) 
49 (E)  (G)  (G) (E) (E) (S) (S) (S) (E) 
50 (S) (E)  (G)  (G) (S)  (G) (E) (E)  (G) 
51 (S) (S)  (G) (S) Excluded (E)  (G) (E) (E) 
52 (S) Excluded (E) (SE) Excluded Excluded Excluded Excluded Excluded 
53  (G) (E) (S) (S) (SE)  (G)  (G)  (G) (S) 
54 (E) (S)  (G) (S)  (G) Excluded (SE) (E) (S) 
55 Excluded (S) (S) (S) (S) (E)  (G) (S) (SE) 
56  (G)  (G)  (G) (E) (S) (S)  (G) (E) (S) 
57 Excluded (E) (S) (S) (S) (S) (E) (SE)  (G) 
58 (E) (S) (S) (E) (S) (E) (S) (E) (S) 
59  (G)  (G) (E) (E)  (G)  (G) (E) (S) (E) 
60 (E) (S)  (G) (S) (S) (S) (E) (S) (S) 
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٠غخخذِْٛ رلاد أٔٛاع  %6.62ٚف١ّا ٠خؼٍك باعخخذاَ أٔٛاع ِٛاد ِؼا٠شة فحص اٌذَ أظٙشث اٌذساعت أْ 
أظٙشث اٌذساعت أ٠عا ًأْ اٌّخخبشاث اٌخٟ . ٠غخخذِْٛ ٔٛع ٚاحذ فمػ%7.66 ِٓ ِٛاد اٌّؼا٠شة فٟ ح١ٓ 
حغخخذَ رلاد أٔٛاع ِٓ ِٛاد اٌّؼا٠شة أظٙشث ٔخائش ِّخاصة ِماسٔت بّٓ ٠غخؼٍّْٛ ٔٛع ٚاحذ بٕاء ػٍٝ 
ِٓ اٌّخخبشاث لا حغخخذَ أٞ ٔٛع ِٓ ِٛاد  %7.6وّا أظٙشث اٌذساعت أْ . ٔخائش ِؤشش الإٔحشاف
ِٓ اٌّخخبشاث حؼًّ ظبػ ِٚؼا٠شة ٌضٙاص  6..0%أْ  أظٙش ححٍ١ً إٌخائشٝ رٌه ػلاٚة ػٍ. اٌّؼا٠شة
حؼًّ ظبػ ِٚؼا٠شة ٌٍضٙاص ِشح١ٓ أعبٛػ١ا ًأِٚشة أعبٛػ١ا ًِٓ اٌّخخبشاث  %0.63ٚأْ  فحص اٌذَ ٠ِٛ١اً 
 .أٚ أح١أاً 
اٌّخخبشاث اٌطب١ت  إْ اٌخٕالط فٟ ػذد الأٔٛاع اٌّغخخذِت فٟ اٌّؼا٠شة أٚ اٌفخشة اٌضِٕ١ت ٌىً ِؼا٠شة ب١ٓ 
ٌمذ أظٙشث ٘زٖ اٌذساعت ظؼف . ٠ش١ش اٌٝ ٚصٛد عٛء فُٙ ٌّبادا ػًّ اٌّؼا٠شة ٌضٙاص ل١اط خلا٠ا اٌذَ
اٌخٛافك ٚػذَ الإٔغضاَ فٟ ِخخبشاث اٌذَ فٟ اٌعفت اٌغشب١ت ٚاٌحاصت اٌٝ بشٔاِش ٚغٕٟ ٌٍضٛدة فٟ 
 .ِخخبشاث اٌذَ فٟ فٍغط١ٓ ٌٍٛصٛي اٌٝ ِغخٜٛ ِشخشن ِٓ اٌخٛافك
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  ػّش ٌٚ١ذ ػبذ اٌشحّٓ اٌضباٌٟ: ػذاد إ
 
  .خاٌذ ٠ٛٔظ. أ: اٌّششف الأٚي
  .ِحّٛد عشٚس. د: اٌّششف اٌزأٟ
  
 الولخص 
ّ٘١ت فحص اٌذَ أحىّٓ . ػا ًػٍٝ الإغلاق فٟ ِخخبشاث اٌذَالأوزش ش١ٛCBC( (٠ؼخبشفحص اٌذَ اٌشاًِ 
ٌزٌه ٚلأّ٘١ت ٘زا . بؼط أِشاض اٌغشغاْٚ ،اٌذَ، اٌؼذٜٚػٍٝ حشخ١ص حالاث فمش  حٗاٌشاًِ بمذس
ِشالبت اٌضٛدة أٚلا ً :ٓ١اٌبشٔاِش ِغخٛ٠١ٓ أعاع١ ٠خعّٓػٍٝ أْ اٌفحص ٚصب إدساس بشٔاِش سلابت اٌضٛدة 
ِشالبت ٌٍفحٛصاث اٌطب١ت بشىً حم١١ُ اٌضٛدة اٌخاسص١ت ِّا ٠ٛفش فٟ بشٔاِش انالإشخشاٌذاخٍ١ت ٚرأ١اً 
، ِٛرٛق بٙا ِخبش٠ت ٔخائش غب١ت٠ٕخش ْ بشٔاِش ِشالبت اٌضٛدة اٌذاخٍ١ت ٠عّٓ ٌٍّخخبش أْ أح١ذ  ،ِغخّش
١ٓ حم١١ُ اٌضٛدة اٌخاسص١ت حٛف١ش اٌخٛافك ٚالإٔغضاَ ٌٕخائش اٌفحٛصاث اٌّخبش٠ت ب بشٔاِش ٠عّٓفٟ ح١ٓ 
 .اٌّخخبشاث اٌطب١ت
إْ اٌذلت ٚالإٔغضاَ ب١ٓ ٔخائش اٌّخخبشاث اٌطب١ت بّا فٟ رٌه ٔخائش فحص اٌذَ اٌشاًِ ٌُ ٠خُ حم١١ّٙا عابما ً.
ٌٚزٌه حٙذف ٘زٖ اٌذساعت اٌٝ حم١١ُ ِذٜ اٌذلت ٚالإٔغضاَ ٌفحص اٌذَ اٌشاًِ . فٍغط١ٓ –فٟ اٌعفت اٌغشب١ت 
. ٠ِٛاً  22ث دٚسة اخخباس اٌفحص رلاد ِشاث ٠فصً وً دٚسة حُ حٛص٠غ رلاد ػ١ٕاث ِٓ اٌذَ ح١ذ حىشس
بؼذ اٌفحص لاِج اٌّخخبشاث اٌّشاسوت بئسعاي ٔخائضٙا ٌ١خُ ححٍ١ٍٙا ٚحفغ١ش٘ا باعخخذاَ ِؤشش الإٔحشاف 
ٌخفغ١ش ) SAQEN-KU(ٚلذ أػخّذ ٔظاَ اٌٍّّىت اٌّخحذة فٟ اٌضٛدة اٌخاسص١ت ) xednI noitaiveD(
ٌٚمذ شاسن فٟ ٘زٖ  ِخخبشاث اٌعفت اٌغشب١ت باعخخذاَ ػ١ٕاث دَ غاصصتفٟ .ٔخائش ِؤشش الإٔحشاف
 . اٌذساعت عخْٛ ِخخبشا ًغب١اً 
ٌمذ ب١ٓ اٌخحٍ١ً الإحصائٟ ٌفحص اٌذَ اٌشاًِ أْ أداء اٌّخخبشاث اٌّشاسوت رابج ٌُٚ ٠طشأ ححغٓ فٟ 
ِٓ اٌّخخبشاث اٌطب١ت حشخشن فٟ بشٔاِش  1..3%أظٙش ححٍ١ً اٌب١أاث أْ . الأداء فٟ اٌضٛلاث اٌزلاد
 . ح١ت اٌّحٍ١تخاسصٟ ٌٍضٛدة اٌخاسص١ت لأْ بشاِش اٌضٛدة اٌخاسص١ت لا حطبك ِٓ لبً الأٔظّت اٌص
